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mykiss) model system, a partial trout ras sequence was identified
using the polymerase chain reaction (PCR).Two synthetic
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information expressed in mRNA. This 5'-terminal partial trout K-ras
nucleotide sequence was 88% homologous to that of the goldfish ras
gene, and less homologous to those of mammalian ras genes.
Based on the partial sequence information of two trout ras genes,
K-ras and H-ras, DNA from trout tumors induced by chemicalcarcinogens,aflatoxinB1(AFB1) and N-methyl-N'-nitro-N-
nitrosoguanidene (MNNG), were analyzed for thepresence of point
mutations. Using the PCR and oligonucleotide hybridization methods,
a high proportion (10/14) of the AFB1-initiated liver tumor DNA
indicated evidence for ras point mutations.Of the 10 mutant ras
genotypes, seven were probed as G to T transversions at the second
position of codon 12, two were G to T transversions at the second
position of codon 13, and one was a G to A transition at the first
position of codon 12.Nucleotide sequence analysis of cloned PCR
products from four of these tumor DNAs provided definitivemutation
evidence in each case, which seemed to occur in onlya fraction of the
neoplastic cells.However, no mutations were detected in exon 1 of
the trout K-ras gene, nor in DNA from trout normal livers.Results
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mutations in trout as in rat liver tumors. By comparison, the mutation
specificity of MNNG in trout liver tumors was for G to Atransitions,
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IN RAINBOW TROUT TUMORS
INTRODUCTION
Ras oncogene and p21.
Oncogenes disrupt the control systems of cell growth and/or cell
differentiation and in this way contribute to the development of cancer
(Bishop, 1987).Identified oncogenes of viral and cellular origin were
grouped on the basis of the nuclear or cytoplasmic localization of the
oncogene encoded proteins (Weinberg, 1985).In the cytoplasm,
these proteins may regulate levels of critical second messenger
molecules; in the nucleus, these proteins may modulate the activity of
the cell's transcriptional factors.Oncogene products can also be
related to a signaling pathway for the cell's response to growth-
stimulating factors (Barbacid, 1987). The ras gene family of 3 closely
related genes, K-ras H-ras and N-ras, has been extensively studied
and appears to play an important role in a significant portion of human
cancers (Barbacid, 1987).The gene family members are located in
different chromosomes in human; the N-ras gene at chromosome 1,
the H-ras gene at chromosome 11, the K-ras gene at chromosome 12
(see Lacal and Tronick, 1988).The ras oncogenes are almost
invariably activated by single base changes (or point mutations) at
specific positions, usually assayed by their ability to induce the
malignant transformation of NIH3T3 cells.Ras gene mutational
activation then results in amino acid substitutions in the p21 ras
protein (Der et al., 1982; Reddy et al., 1982) without an affect on the2
level of expression of these genes (Tabin et al., 1982; Taparowsky et
al., 1982).
Identification.
It was only in 1982 that isolation of the human oncogene, ras, was
reported (Goldfarb et al.,1982; Santos etal.,1982; Shih and
Weinberg, 1982; Parada et al.,1982).Originally, ras genes were
identified as the transforming principle of the Harvey and Kirsten
strains of rat sarcoma viruses, two acute transforming retroviruses
generated by transduction of the rat H-ras 1 (Dhar et al., 1982) and K-
ras2 (Tsuchida etal.,1982) cellular genes, respectively.The
homologue of the viral Kirsten ras (v-K-ras) gene was then found in the
human lung carcinoma cell line, Ca lu-1 (Shimizu et al., 1983c), and
that of the viral. Harvey ras (v-H-ras) was in the human bladder
carcinoma cell lines, T24 and EJ (Reddy et al., 1982; Taparowsky et
al., 1982; Tabin et al., 1982).The N-ras locus found in SK-N-SH
neuroblastoma cells, however, has not been transduced by retroviruses
(Taparowsky et al., 1983; Shimizu et al., 1983b).
Highly conserved sequence.
Three ras genes have been identified in several mammalian
genomes; H-ras 1 in human (Tabin et al., 1982; Goldfarb et al., 1982;
Shih and Weinberg, 1982; Capon et al., 1983a; Pulciani et al., 1982b;
Reddy, 1983; Yuasa et al., 1983) and in rat (Ruta et al., 1986; Sukumar
et al., 1983; DeFeo et al., 1981), K-ras2 in human (McGrath et al.,
1983; Shimizu et al., 1983a; Nakano et al., 1984; Capon et al., 1983b;
McCoy et al., 1984) and in rat (Tahira et al., 1986) and in mouse
(George et al., 1985), and N-ras in human (Shimizu et al., 1983b; Hall
et al., 1983; Taparowsky et al., 1983; Brown et al., 1984; Padua et al.,3
1985), in mouse (Guerrero et al., 1984; Guerrero et al., 1985) and in
rat (McMahon et al., 1990b).
Ras gene family shares regions of nucleotide homology and
nucleotide divergence within coding sequences and have a common
intron/exon structure, indicating that they may have evolved from a
similarly spliced ancestral gene.There is strong conservation of the
entire amino acid sequence between homologous ras genes in distant
species, despite a high frequency of third-base neutral changes
(Barbacid, 1987).For instance, the nucleotide sequence of goldfish
ras protein shows nearly 80% homology with the sequences of
mammalian H-, K-, and N-ras genes (Nemoto et al., 1986).
p21 and its activation.
The ras gene products have been identified as proteins of 188 or
189 amino acid residues, generally known as p21. They are located at
the inner side of the plasma membrane where they are anchored into
the lipid bilayer by a covalently attached palmitic acid at the carboxy
terminus. The proteins can bind GTP and GDP with high affinity and
possess GTPase activity (McGrath et al., 1984).They share limited
amino acid homology with G-like proteins, which are known to
transduce signals from various cell-surface receptors to adenylate
cyclase (Lacal and Tronick, 1988).
The high degree of evolutionary conservation of ras genes and their
products implies that p21 may play a fundamental role in cellular
proliferation among vertebrates (Barbacid, 1986).In particular, the N-
terminal 85 amino acid residues of p21 is highly conserved, and thus
is believed to be an essential region for the function of p21.The
region about positions 59-63 adjoins a site for autophosphorylation by4
GTP, whereas the sequence around amino acids 12 and 13 may
neighbor the GTP binding site, since this region has amino acid
homology to known nucleotide binding proteins (Wierenga and Hol,
1988; Shih et al., 1982). These regions might therefore be expected
to be involved as target sites for carcinogenic activities of ras, gene.
Sequences of ras gene in exon 1 and 2 among several species are
compared in Table 1.
It has been postulated that normal ras proteins exist in an
equilibrium between 'excited' and 'relaxed' states depending on
whether they bind GTP or GDP, respectively (Weinberg, 1985).
Conversion of the 'excited' to the 'relaxed' state is thought to be
mediated by an intrinsic GTPase activity of ras proteins.Point
mutations to activate normal ras proto-oncogenes into oncogenes
either block the intrinsic GTPase activity, thus preventing the normal
deactivation of these proteins (Sweet et al.,1984) or reduce the
affinity for GDP and GTP (Weinberg, 1985) to produce a constitutively
activated ras gene product.
The availability of large quantities of purified p21 protein through
the expression of ras genes in bacteria made it possible to more
readily investigate the relationship of GTP binding and hydrolysis to
biological function.Microinjection of purified mutant p21 proteins
into NIH3T3 mouse fibroblastsledtotransient morphologic
transformation and cell proliferation (McGrath et al.,1984).The
presence of a Gly residue at position 12 appears to be necessary for
the normal function of ras proteins (Tabin et al., 1982).Substitution
of Gly12 by any other amino acid residue (with the exception of Pro)
results in a significant structural change in an essential domain of theTable 1. Sequence comparison in exon 1 and part of exon 2 of ras
gene among several species.
exon 1:
123456789 10 11 12 13 14 15 16 17 18 19
Ivbt.ThrGluTyrLysLeuValValValGlyAlaGlyGlyValGlyLysSerAlaLeu
HK:ATGACTGAATATAAPiaLTGTGGT
RK. -G-
MK. -G-
TGGCGTAGGCAAGAGIGCCTTG
HH: -G -G---G--G--G--C -C -C -T -G- -GC--
RH: A -IC -G- G--C A -G- A -C
HN:
MN:
-G- -C -G- G-
-G--C -G- G-
A TT -G--A--C --AC
A TT -G--A--C---C--
Gf: A -C- C -A---G-----A------G- TC C
Ch:-----C--G--C--G--G- -Cr- A T -C--G-----C--T---
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37
ThrIleGlnLeuIleGlnAsnHisPheValAspGluTyrAspoProThrIleGlu
HK:ACGATACAGCTAATTCAGAATCATT=GACGAATATGATCCAACAATAGAG
RK: -C T T -G-
MK: -C T -G--C -CT -G-
HH:--C--C-----G--C -C -C -CC -T
RH: -C -G--C -C -G-
HN: -A -C -C -C -C A T
MN: -C -C -C
-C
-C
Gf: -C- -C -A- -C -C -C -C -C -C -C
Ch: -C -C TT -G- -C -CC
56
Table 1. Sequence comparison in exon 1 and part of exon 2 of ras
gene among several species (Cont.).
part of exon 2:
38 39 40 41 42 43 44 4546 47 48 49 50 51 52 53 54 55 56
Asp SerTyrArgLysG1nValValIleAspGlyGluThrgysLeuLeuAspIleLeu
HK:GATTCCTACAGGAAGCAAGTAGTAATTGATGGAGAAACCTGTCTCTTGGATATTCTC
RK: -C A
MK: --C A
HH: -C -G--G--C -G--G--G--C -G-----C--C--G
RH: -C -C A -G- C -G--G--G T -AC -C -CT -A
HN: T A A -G- T -A T T-G-----C--A--G
MN: T --C A -Cr G- T -G- -C --GC -C --A--G
Gf : --C -G--G- G- -G--G--G -Cr-C -CT-G
Ch A -CC -C -G- T-GC----C--C--G
57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
AspThrA1aGlyGlnGluGluTyrSerAlaMetArgAspG1nTyrMetArgThrGly
HK:GACACAGCAGGTCAAGAGGAGTACAGTGCAATGAGGGACCAGTACATGAGGACTGGG
RK. A
MK. A
HH:--T--C--C--C--G- -C -C-C -C- C -C
RH: A T -C-C -C -C --A-
HN :-T T A A -C A A A C
MN: T A -C A A C
Gf : T -G- -C -C T A A
Ch: -T -G -G- -G- -G- -C-C A A -G---7
Table 1. Sequence comparison in exon 1 and part of exon 2 ofras
gene among several species (Cont.).
HK:
76 77 78 79
GluGlyPheLeu
RK: --- - - - - --
HH: -C --G
RH: -C -C
HN: -A- -G- -C -C
MN:- -A- -G- -C -C
Gf: -C --C
Ch: -A- -A- -C -G
Ref.
HK : Human K-ras (Capon et al., 1983b; McCoy et al., 1984)
RK : Rat K-ras (Tahira et al., 1986)
MK : Mouse K-ras (George et al., 1985)
HE Human H-ras (Tabin et al., 1982; Capon et al., 1983a)
RH : Rat H-ras (Sukumar et al., 1983; Ruta et al., 1986)
EN : Human N-ras (Brown et al., 1984; Gambke et al., 1985)
MN : Mouse N-ras (Guerrero et al., 1985)
Gf : Goldfish ras (Nemoto et al., 1986)
Ch : Chicken ras (Westaway et al., 1986)8
p21 protein and causes the oncogenic activation of these molecules,
suggesting a requirement for an alpha-helical polypeptide structure in
this region (Seeburg et al., 1984).Similarly any replacements of the
normal glutamine at codon 61 of H-ras, except by glutamic acid and
proline, was found to cause activation (Der et al., 1986).
Mutational analysis of ras oncogene.
Most of these transforming genes have been identified as mutated
alleles of cellular ras genes using DNA transfection of the NIH3T3
mouse fibroblast cell line.Generally, the activating mutations occur in
the codons for amino acid residues 12, 13 or 61 of the protein
(Seeburg et al., 1984; Bos et al., 1985; Brown et al., 1984), although
potential sites for activation have also been identified at codons 59
(Fasano et al., 1984), 116 (Walter et al., 1986), and 119 (Sigal et al.,
1986a and 1986b) by in vitro mutagenesis studies. Not all mutations
at different sites may be equally effective at inducing tumorigenic
transformation (Fasano et al., 1984). Table 2 describes the mutational
activations of ras genes in human primary tumors. Tumor cell lines
were not included because of the possibility that mutation occurred
during later passages of cell lines (Pulciani et al., 1982a; Albino et al.,
1984; Janssen et al., 1987a) or that cell lines obtained may represent
only a subset of a particular tumor type (Tainsky et al., 1984).
Tissue-specific mutation incidence.
It can be seen from Table 2 that the various target tissues showed
prevalent activation of one particular type of ras oncogene at certain
incidence.Smit et al. (1988) mentioned that "tissue-specific factors"
such as susceptibility of the various genes to particular chemical
mutagens or activity of certain DNA repair mechanisms could9
Table 2. Human ras oncogene mutations.
Tissue Mutation
Site(s)
Frequency
(%)
Mutation
Events
Detection
Methods
Ref.
Lung K 12 5/10 (50) early Oligo/PCR [1]
Colon K 12 6/6 (100) earlySeq/PCR [2]
K 12 9/27 early Oligo/PCR [3]
K 61 1/27
N 12 1/27
11/27 (41)
K 12 early Seq/PCR [4]
adenoma 9/12 (75)
carcinoma 26/40(65)
K 12 26/66 (40)early(D)RNAse 151
68/172 (40) Oligo/PCR [6]
adenomaK 12 17/80
K 13 6/80
1(61, N122/80
25/80 (31)
carcinomaK 12 30/92
K 13 7/92
N 13 2/92
N 61 2/92
1(61, N122/92
43/92(47)
PancreasK 12 47/63 (75)both(D)Oligo/PCR [7]
K 12 28/30 (93) Oligo/PCR [8]
K 12 21/22 (95)early RNAse/PCR [9]
RFLP/ Oligo
ALL N 12 4/33 both(D)Oligo/PCR [10]
N 13 3/33
6/33 (18)
N 12 2/19 (11) Oligo [11]10
Table 2. Human ras oncogene mutations (cont.).
Tissue Mutation
Site(s)
Frequency
( %)
Mutation
Events
Detection
Methods
Ref.
AML N 61 3/9 Oligo/PCR [12]
N 12 1/9
H 12 1/9
5/9 (55)
N 13 6/45 Oligo [13]
N 61 4/45
K 12 2/45
12/45 (27)
N 12 13/52 both(D)Oligo/PCR [14]
N 13 1/52
14/52 (27)
N 13 5/8 (62) Oligo/PCR [15]
N 3/6 Transf [16]
CML H 12 0/25 (0) none RFLP [17]
ras 0/26 (0) Oligo/PCR [12]
MDS N 13 3/8 (38) earlyTransf [18]
N 12 1/15 (7) Oligo/PCR [12]
K 13 1/1 earlyTransf [19]
Oligo/PCR
Breast K 13 1/40 (2) none Oligo/PCR [20]
ras 0/16 (0) Transf/RFLP[21]
Stomachras 0/37 (0) Transf [22]
Esophagusras 0/25 (0) Oligo/PCR [23]
Urinary H 61 2/38 (5) Transf [24]
Tract
Kidney H 12 1/16 RFLP [25]
H 61 1/16
2/16 (13)11
Table 2. Human ras oncogene mutations (cont.).
Tissue Mutation
Site(s)
Frequency
(%)
Mutation
Events
Detection
Methods
Ref.
Liver K12,N612/34 (6) none Oligo/PCR [26]a
N 3/10 Transf [27]
ras 0/12 noneSeq/PCR [281a
K 12 5/9 [281b
K 61 1/9
6/9 (67)
Skin N12,13,617/37 (19) early(D)Oligo/PCR [29]c
H 61 1/10 (10) earlyTransf [30]d
N 61 1/13 (8) laterTransf [31]
Thyroid K, H, N early Oligo/PCR [32]
adenomaN 61 3/24
H 61 2/24
H 12 1/24
K 12 1/24
N 12 1/24
8/24 (33)
carcinomaH 12 3/20
H 61 3/20
K 12 2/20
N 12 1/20
N61 1/20
10/20 (50)
a : Hepatocellular carcinoma, b : Cholangiocarcinomas, c :
Melanomas, d : Keratoacanthomas.
ALL : Acute Lymphoblastic Leukemia; CML : Chronic Myeloid
Leukemia; MDS : Myelodysplastic syndrome (or preleukaemia).
D : simultaneous Double Mutations.12
RFLP : Restriction Endonuclease Digestion; Oligo: Mutation-specific
Oligonucleotide Hybridization; Transf : NIH3T3 Transfection
Biological Assay; Seq : Direct Sequencing of PCR products; RNAse :
Mismatches Cleavage.Assay
Ref.
[1] Rodenhuis et al., (1987); [2] Burmer et al., (1989); [3] Bos et al.,
(1987a); [4] Burmer and Loeb, (1989); [5] Forrester et al., (1987); [6]
Vogelstein et al., (1988); [7] Grunewald et al., (1989); [8] Smit et al.,
(1988); [9] Almoguera et al., (1988); [10] Neri et al., (1988); [11]
Rodenhuis et a1., (1986); [12] Janssen et al., (1987b); [13] Bos et al.,
(1987b); [14] Farr et al., (1988); [15] Bos et al., (1985); [16]
Needleman et al., (1986); [17] Browett et al., (1989); [18] Hirai et al.,
(1987); [19] Liu et al., (1987); [20] Rochlitz et al., (1989); [21] Kraus
et al., (1984); [22] Sakamoto et at, (1986); [23] Hollstein et al.,
(1988); [24] Fujita et al., (1985); [25] Fujita et al., (1988); [26] Tsuda
et al., (1989); [27] Gu et al., (1986); [28] Tada et al., (1990); [29] van't
Veer et al., (1989); [30] Leon et al., (1988); [31] Raybaud et al., (1988);
[32] Lemoine et al., (1989).13
influence the incidence of ras activation among various target organs.
Another explanation for tissue-specific activation was based on the
linkage between the growth factor receptors and p21, which indicates
that hormonal status or the differentiation state of the target tissue is
important in determining the specificity (Balmain and Brown, 1988).
Neri et.al.(1988) suggested that important differences in the
frequency of ras gene mutation may exist between tumors derived
from different tissues or between histopathological subtypes of tumors
derived from the same tissues. However, Bos (1988) concluded in his
review that there is no strict specificity for activation of particular ras
genes in tumors from particular tissue.In many malignancies any of
the three ras genes can be activated, particularly in all stages of human
thyroid tumorigenesis (Lemoine et al., 1989) and human embryonic
rhabdomyosarcomasshowingfeaturesofskeletalmuscle
differentiation (Stratton et al., 1989).
A considerable number of activated ras genes have been detected in
DNA from lung, colon, and pancreatic carcinomas (Pulciani et al.,
1982a).In most cases the K-ras gene was found to be activated at a
high incidence rate.In a recent animal study with individuals
chronically exposed by inhalation to tetranitromethane, which mimics
human exposure to a chemical in the workplace, all of the rat and
mouse lung tumors tested had a K-ras oncogene mutation in the
second base of codon 12 (Stowers et al.,1987).In other animal
studies causing tumor formation in lungtissue, K -ras, oncogene
mutations were consistently involved (Belinsky et al., 1989; You et al.,
1989). Mutational K-ras activation in these tissues was suggested to be
an important early event in the pathogenesis of adenocarcinoma14
(Rodenhuis et al., 1987; Burmer et al., 1989; Bos et al., 1987a; Burmer
and Loeb, 1989; Forrester et al., 1987). Concurrent double mutations
observed in the same tumor, however, suggested that some mutations
do arise after the initial transforming mutation event (Grunewald et al.,
1989).
The ras gene activation in hematopoietic malignancies, except
chronic myeloid leukemia (CML), predominantly involves the N-ras
gene at a substantial frequency (20-50%) (Neri et al., 1988; Janssen et
al., 1987b; Bos et al., 1987b; Farr et al., 1988; Bos et al., 1985; Brown
et al., 1984).The H-ras activation is rare in these malignancies
(Browett et al., 1989). A high incidence of N-ras activation by the
chemical carcinogen N-methyl-N-nitrosourea (MNU) was also
reported to occur in mouse lymphomas (Guerrero et al., 1984), which
suggests that N-ras, rather than the other ras genes, may be critically
involved in the control of proliferation and differentiation of cells in
the haematopoietic lineage.This observation may also indicate that
environmental chemical agents may be responsible for the induction of
the mutations (Bos, 1989).
Ras gene activation is not, however, believed to be involved in all
human tumors. A very low percentage or none of urinary tract (Fujita
et al., 1985), breast (Rochlitz et al., 1989; Kraus et al., 1984) and
stomach carcinomas (Sakamoto et al., 1986) examined contained ras
gene mutations, which suggested that tumorigenesis in different
tissues have different pathogenic mechanisms with different
frequencies of ras gene mutations (Bos et al., 1987a).
The very limited studies of human hepatocellular carcinoma (HCC)
to date have indicated that point mutations of ras genes were very rare15
or not found at all, suggesting that au mutation may not be involved in
all human HCC (Tsuda et al., 1989), and that a new transforming gene
may be involved (Ochiya et al., 1986).However, cholangiocarcinomas
arising from the epithelium of the intrahepatic bile duct showed a
high frequency of K-ras mutation (Tada et al., 1990). The observed
simultaneous mutation of N-ras and c-myc suggested their cooperation
for the malignant phenotypic alteration in some human HCC (Gu et al.,
1986).
Particularly in the cases of low mutation incidence in liver and
stomach primary tumors, the activation of ras genes is argued not to
be an obligatory event and not the only event in tumor formation (Bos,
1989). Other unknown activating event(s) may have the same ultimate
effect (Ochiya et al., 1986; Sakamoto et al., 1986).But when a ras
gene mutation occurs it can contribute to both early and advanced
stages of human carcinogenesis (Bos, 1988). Cells with a mutated ras
gene and thus the type of mutation are selected. This selection may
be cell type specific and influence the tissue-specific mutation
spectrum (Bos, 1989).
In an increasing number of malignancies it has been shown that one
allele of a recessive "tumor suppressor" has been deleted and in this
way chromosomal loss may contribute to the development of bladder
(Fearon et al., 1985) and breast carcinomas (Theillet et al., 1986). A
tumor-suppressor gene located on the same chromosome as H-ras,
chromosome 11, can suppress the tumorigenic phenotype (Saxon et
al., 1986). The loss of an H-ras allele as well as the tumor-suppressor
gene correlates with the most aggressive primary carcinomas.The16
incidence of mutationally activated H -ras, alone is quite low in bladder
and breast carcinoma.
As shown in Table 2, activated au genes are found in most, if not
all, types of solid tumors but the incidence rates vary considerably
(Bos, 1988). No apparent correlation was found between thepresence
of mutant oncogenes and the degree of invasiveness of the tumors
(Forrester et al., 1987).
Coexistence of normal and mutated alleles,
Many human primary tumors contain an activated ras gene allele as
well as the corresponding normal allele (Stowers et al., 1987; Neri et
al., 1988; Rochlitz et al., 1989). Since a single copy of the mutated ras
oncogene is sufficient to impart oncogenicity even expressed under a
weak transcriptional promoter, the mutated allele behaves ina
dominant fashion (Tabin and Weinberg, 1985).It was reported that
during progression of a tumor the ratio between the normal and the
mutant allele in the tumor cell population shifts towards the mutated
allele (Bos et al.,1987a; Almoguera et al.,1988).That the ras
mutation has been seen to be acquired by a subpopulation of malignant
cells (Neri et al.,1988) suggests a selective growth advantage
(Rodenhuis et al., 1987).
Alternatively over-expression of normal p21 can induce the
complete cellular transformation, but apparently no increase in mutant
p21 expression is required (McKay et al.,1986).In a gastric
carcinoma, for instance, a single mutated K-ras allele was found as well
as a 30-50 fold amplified normal allele (Bos et al., 1986). The elevated
expression of normal ras protein can play at least a permissive role in
the induction of tumors (Spandidos and Wilkie, 1984; Cohen and17
Levinson, 1988).Therefore, it seems likely that the ratio between
normal and activated alleles or, eventually, a concentration of the
mutated gene product is important for the phenotype of a tumor cell
(Bos, 1988).
In normal tissue of a patient with activated K-raa oncogene in lung
carcinoma, ras gene mutations were not found (Santos et al., 1984).
Therefore, significant numbers of non-neoplastic cells, usually mixed
in solid tumor specimens, would dilute any positive signal in the
transfection assay (Verlaan-de Vries et al.,1986) and show the
apparent heterozygosity. Or selective pressure may actually favor the
loss of the ras oncogene during tumor development and the mutated
alleleis selectively lost (Neri etal.,1988).Sometimes as an
experimental error the DNA from primary human tumors are slightly
degraded during surgery and subsequent tissue handling (Bos et al.,
1987a), perhaps obscuring the presence of activated ras.
The temporal relationship between the ras gene activation event
and the disease process; i.e., whether activation occurs before, at the
time of, or after the establishment of the malignant clone is an
intriguing question. Barbacid (1986) strongly suggested in his review
that ras gene activation plays a causative role in the development of
neoplasia.The notion that mutant ras genes are involved in the
initiation of tumorigenesis has been fostered by several studies; (1)
Adenoma-Carcinoma Concept : K-ras mutations have been uncovered
in premalignant tissue adjacent to human colon carcinomas (Bos et al.,
1987a; Forrester et al., 1987; Burmer and Loeb, 1989), in very small
lung tumors that had not metastasized (Rodenhuis et al., 1987) and in
the preleukaemic state of a patient who progressed to acute leukaemia18
(Liu et al., 1987). (2) Chemical Carcinogenesis : Based on the fact that
the transforming allele was not present in the germ line but was
generated somatically (Gambke et al., 1985; Kraus et al., 1984; Liu et
al.,1987), animal studies using chemical carcinogenesis showed
reproducible and high incidences of ras gene mutations (see Table 3).
A single dose of chemical having a short half-life and the induced
predictable base changes by its intrinsic chemical reactivity indicates
that the direct reaction between DNA and chemical intermediates
initiate the ras gene mutation (Zarbl et al., 1985).(3) Ubiquitous
Presence :Particularly in exocrine pancreatic carcinomas, mutant K-
ra s alleles were discovered at a high incidence, in histologically
different tumor regions, and in both primary tumors and their
corresponding metastases (Almoguera et al., 1988).
Apparently, activation of a ras gene is an important step in tumor
progression which predisposes a particular cell to become a tumor
(Bos, 1988).However, this mutation already exists in most of the
premalignant lesions (Balmain etal.,1984) and a subsequent
secondary (or complementary) genetic event may be required for
carcinogenesis to progress (Klein and Klein,1984; Bos, 1988).
Alternatively, certain epigenetic factors such as tumor promoters may
overcome the normal control state (Barbacid, 1986).For instance,
longitudinal study at several different stages of colorectal tumor
development suggests mutant ras genes are actively involved and
continuously contribute to the process of tumor progression including
the metastatic process (Vogelstein et al.,1988).In addition the
simultaneous presence of two differently mutated ras gene alleles in
the same tumor suggests that the activating event can occur at several19
points in the process of tumor formation (Rodenhuis et al., 1987;
Grunewald et al., 1989).
By contrast, ras activation is involved only in the final stages of
tumor progression in breast cancer where activating ras, mutations are
rarely associated with tumor initiation or maintenance but occur at the
stage of metastatic progression (Rochlitz et al.,1989).Similar
conclusion was reached by Albino et al. (1984).
Double mutations in one tumor sample.
Concurrent activation of two ras gene sequences or two different
positions by point mutations is known to occur in human carcinoma
cell lines (see Table 2). The simultaneous presence of activated N-ras
and K-ras oncogenes in the same tumor DNA has been reported in
human acute myelocytic leukemia (AML) cell line (Janssen et al.,
1987a) and in human colon carcinoma (Forrester et al., 1987). Two
mutations detected in both codons 12 and 13 (Neri et al., 1988) or in
both codons 12 and 61 (Farr et al., 1988) of an N -ras, gene were
present in two distinct alleles of the same AML tumor.
Probably there are more than two complementation groups among
the known oncogenes (Klein and Klein, 1984) and an activated ras
gene alone cannot sustain the total neoplastic transformation (Leon et
al.,1988; Land etal.,1983).In the multistep process of
carcinogenesis, different oncogenes are sequentially, or concurrently,
activated and the interactions of oncogene products determine the
cell's phenotype (Husain et al.,1989; Levinson, 1987).Like the
cooperation between ras and mvc oncogenes (Land et al., 1983) one
activated oncogene is complemented by other altered member of
oncogenes (Weinberg,1989).Alternatively, a concurrent point20
mutation in codon 12 and 61 could significantly increase the
transforming ability of respective proteins as compared to the ras
protein altered solely in position 12 or 61 (Farr et al.,1988).
Interestingly, triple mutation in a single allele of rat N -ras, gene was
reported at codon 8, 13 and 18, which are the unusual mutation sites
of the ras gene family (McMahon et al., 1990b).
Target sequence of carcinogens.
It is generally accepted that many carcinogens are mutagens. The
mixed function oxidases (MFG), located in the endoplasmic reticulum
of most cells, generally metabolize the carcinogens to yield activated
epoxides.This membrane bound system requires cytochrome P-450
and has greatest activity in liver (see Wade and Dharwadkar, 1986). A
significant number of chemical carcinogens are known to react with
DNA bases to form adducts, some of which are highly mutagenic due to
their miscoding propertiesorthelimitedfidelityof repair
polymerases (reviewed in Singer and Kusmierek, 1982). Topal (1988)
suggested the "positional mutation bias" in his review that some DNA
sequence may present particular base positions as easy targets to the
mutagen and/or keep mutagenic lesions from repair activities so that
the lesions persist.
As a target sequence of carcinogens, the ras gene mutations are
often involved in chemically-induced tumors.The reproducible
activation of ras oncogenes in carcinogen-induced tumors has made it
possible to correlate their activating mutations with the known
mutagenic effects of certain carcinogens (Table 3).Recently, Guerrero
and Pellicer (1987) reviewed the activation of ras oncogenes in
carcinogen-induced animal tumors.21
Table 3. Point mutations in ras genes by chemical carcinogens.
MutagenSpecies & ras Gene Base Incidence Ref.
Tissue / SitesChange Rate (%)
AFB1 rat liver K12/1,2 G->A, G->T 2/11 (18) [1]
AFB1 rat liver K12/2
N
AFB1 rat liver K12/1
K12/2
N13
AFB1 E. coli
AFB1 E. coli
Polycyclic Hydrocarbons
DMBA mouse skinH61/2
DMBA mouse skinH61/2
DMBA rabbit skin H61/2
MCA mouse K
thymomas
BaP mouse lung K12/1
(strain A) K12/2
K12/2
BaPDE CHO cell line
BaPDE human H12/2
fibroblast cell line
BaPDE monkey
kidney cell line
BaPDE E. coli
G->A 1/4(25)
3/4
4/4(100)
G->T 1/8
G->A 2/8
G->A, G->T 5/5
8/13(62)
G->T 169/187 (89)
G->A 12/187(6)
G->T 66/126 (52)
G->A 54/126 (43)
A->T 33/37 (90)
A->T 3/4 (75)
A->T (60)
(83)
G->T 8/13
G->T 1/13
G->A 4/13
13/13 (100)
G->T 10/14 (71)
G->T 2/11 (18)
G->T (34)
G->C (34)
G->A (22)
G->T 62/96 (65)
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[12]
[13]
[14]22
Table3.Point mutations in ma genes by chemical carcinogens (cont.).
MutagenSpecies &
Tissue
ras Gene
/ Sites
Base
Change
Incidence
Rate (%)
Ref.
HO-AAFmouse liver H61/1C->A 7/7 (100) [15]
(B6C3F1)
AF E. coli G->T 14/17 (82) [16]
AcO-TFAhuman G->T 32/49 (65) [17]
-AF kidney cell line G->A 9/49 (18)
G->C 8/49 (16)
DNP rat
fibrosarcoma
K12/1G->T 1/7 (14) [18]
Spontaneous
H61/1C->A 9/27 [19] mouse liver
(B6C3F1) H61/2A->G 3/27
H61/2A->T 3/27
15/27 (56)
mouse liverH61/1 C->A 19/50 [20]
(B6C3F1) H61/2A->G 11/50
H61/2A- >T 2/50
32/50 (64)
mouse lung K12/2G->A 3/10 [10]
(strain A) K12/2G->T 2/10
K12/1 G->C 1/10
K61/2A->G 2/10
K61/3A->T 1/10
9/10 (90)
Nitroso Compounds
1) Nitrosamines
DEN mouse liver H61/1C->A 7/33 [21]
(B6C3F1) H61/2A->G 3/33
H61/2A->T 4/33
14/33 (42)23
Table 3. Point mutations in ras genes by chemical carcinogens (cont.).
MutagenSpecies &
Tissue
DMN -OAc rat liver
adenoma
carcinoma
cholangioma
NMAB E. coli
MBNA rat esophagus
2) Nitrosoureas
MNU rat mammary
MNU rat mammary
MNU mouse lung
(strain A)
ENU E. coli
3) Nitrosoguanidine
MNNG E. coli
MNNG E. coli
MNNG E. coli
PNNG E. coli
Carbamate Compounds
Urethanemouse skin
vinyl mouse liver
carbamate (B6C3F1)
ras Gene
/ Sites
Base
Change
Incidence
Rate ( %)
Ref.
[22]
K12/2G->A 2/137
K12/2G->A 7/93
K12/2G->A 2/10
11/240 (5)
G->A 169/171 (99)[23]
H12/2G->A 18/18 (100)[24]
H12/2G->A 9/9 (100) [25]
H12/2G->A 36/36 (100)[26]
K12/2G->A 15/15 (100)[10]
A->C 12/29 (46)[27]
G->A 164/167 (98)[28]
G->A 121/123 (98)[29]
G->A 34/37 (92)[30]
G->A 65/89 (73)[29]
H61/2A->T 13/14 (93)[31]
H61/2A->T 6/7 [15]
H61/2A->G 1/7
7/7 (100)24
Table 3. Point mutations in ras genes by chemical carcinogens (cont.).
MutagenSpecies &
Tissue
ras Gene
/ Sites
Base
Change
Incidence
Rate (%)
Ref.
ethyl mouse lung K61/1A->T 7/10 [10]
carbamate (strain A) K61/2A->G 2/10
K12/2A->G 1/10
10/10(100)
CHO cell line : Chinese Hamster Ovary cell line.
MCA : 3-methylcholanthrene; HO-AAF : N-hydroxy-2-
acetylaminofluorene; AF : N-2-aminofluorene; AcO-TFA-AF: N- acetoxy-
N-trifluoroacetyl-2- aminofluorene; DNP :1,8-dinitropyrene; DEN : N-
nitrosodiethylamine; DMN-0Ac : methyl
NMAB : N-nitroso-N-methyl-N-acetoxybenzylamine; MBNA:
methylbenzyl-nitrosamine; ENU : N-ethyl-N-nitrosourea; PNNG: N-
propyl-N'-nitro-N-nitrosoguanidine.
Ref.
[1] McMahon et al., (1987); [2] Sinha et al., (1988); [3] McMahon et
al., (1990b); [4] Foster et al., (1983); [5] Sambamurti et al., (1988); [6]
Quintanilla et al., (1986); [7] Bizub et al., (1986); [8] Leon et al.,
(1988); [9] Eva and Trimmer, (1986); [10] You et al., (1989); [11]
Carothers and Grumberger, (1990); [12] Stevens et al., (1988); [13]
Roilides et al., (1988); [14] Eisenstadt et al., (1982); [15] Wiseman et
al., (1986); [16] Bichara and Fuchs, (1985); [17] Mah et al., (1989);
[18] Tahira et al., (1986); [19] Reynolds et al., (1986 and 1987); [20]
Fox et al., (1990); [21] Stowers et al., (1988); [22] Watatani et al.,
(1989); [23] Horsfall and Glickman, (1988); [24] Wang et al., (1990);
[25] Sukumar et al., (1983); [26] Zarbl et al., (1985); [27] Eckert et al.,
(1989); [28] Burns et al., (1987); [29] van der Vliet et al., (1989); [30]
Richardson et al., (1987); [31] Bonham et al., (1989).25
Direct evidence that exposure to chemical carcinogens can cause
activation of ras genes was provided by the demonstration that in vitro
modification of a plasmid containing the normal cellular H-ras proto-
oncogene withultimatecarcinogens generatestransforming
oncogenes when the modified DNA is transfected into NIH3T3 cells
(Eisenstadt et al., 1982; Marshall et al., 1984; Vousden et al., 1986;
Ireland et al., 1988).However, spontaneous point mutations occur
after the transfection of this vector into the NIH 3T3 cell line.This
results from the DNA replication infidelity during repair of the
transfected DNA damaged by cellular nucleases (Hauser et al., 1987).
The findings that certain chemicals induced somatic mutations of ras
oncogenes in several experimental animal systems provide evidence
that direct interaction of these chemicals with DNA may be crucial to
the initiation of carcinogenesis (Bos, 1988).The type of mutation
observed has been shown to correlate strongly with the known
chemical behavior of the carcinogen used (Bizub et al., 1986; Sukumar
et al., 1983; Wiseman et al., 1986; Quintanilla et al., 1986).In a
recent review, Basu and Essigmann (1988) pointed out the necessity
of novel synthetic approaches that will use site-specifically modified
oligonucleotides as probes for the structural and biological effects of
chemical DNA adducts. The approach for establishing the relationship
between adduct structure and biological effects is to situate individual
adducts or their intermediate products at defined sites in genomes,
allow enzymatic processing to occur in vivo, and then assess the
resulting genetic changes.The structures of three carcinogens
involved in this project are illustrated in Figure 1.26
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Figure 1.Structure of chemical carcinogens.27
Aflatoxin B1 (AFB1)
AFB 1 is a metabolic product of the fungal genus Aspergillus, and a
potent hepatocarcinogen in the most susceptible animals as an
alkylating mutagen. Modification of DNA by AFB1 requires metabolic
activation by MFO producing AFB1-8,9-epoxide.This reactive
electrophile attacks almost exclusively the N7 atom of guanine in the
double-stranded DNA molecule forming an bulky N7-guanyl AFB1
adduct (Refolo et al., 1985; Misra et al., 1983; Groopman et al., 1981;
Croy et al., 1978; Croy and Wogan, 1981).
Planar aromatic molecules such as anthracenes and benzopyrenes
present in soot are able to intercalate between the stacked bases of
the DNA double helix and bring about its partial unwinding.
Intercalation of activated aflatoxins may be a significant transition state
preceding AFB1-DNA covalent bond formation (Yu et al., 1990) because
the overall rate of adduct formation with single-stranded DNA is
greatly diminished (Marien et al., 1987) and the intercalating dye,
ethidium bromide, inhibits the reaction of AFB1 with DNA (Misraet
al., 1983).
A 10-fold variation in the frequency of AFB1-8,9-epoxide attack at
particular guanyl sites was observed, and was suggested to be
dependent on the flanking nucleotides of the site. A strong site for
AFB1 modification is considered to be a guanine residue that has one
or more adjacent G:C base pairs (Refolo et al., 1985). The observed in
vitro sequence specificity is likely to occur in vivo (Muench et al.,
1983; Marien et al., 1987).
Inhibition of DNA replication by AFB1 is directly attributable to N7-
guanyl-AFB1 adducts or their secondary reaction products, such as28
imidazole ring-opened formamidopyrimidine (FAPY)-aflatoxin (Croy
and Wogan, 1981). The primary N7-guanine lesion has an in vitro half-
life of only 8 hrs at 37 °C at pH 7.3 (Wang and Cerutti, 1980).It has
been postulated, therefore, that this primary lesion may be lost
through three major pathways (Wang and Cerutti, 1980): (1) simple
removal of aflatoxin dihydrodiol, leaving an intact DNA guanine behind
(detoxification); (2) guanine imidazole ring opening to yield the more
stable FAPY lesions (Sambamurti et al., 1988); and (3) loss of guanine
to yield an apurinic (AP) site (Groopman et al., 1981; Sinha et al.,
1988).The FAPY-aflatoxin adduct has been detected in human
hepatocarcinoma DNA (Lee et al., 1989), and has been shown to be
nearly equally mutagenic as the primary adduct (Sambamurti et al.,
1988).
Insight into the effect of damage to genetic information requires
analysis of the interactions of cellular replication and repair processes
with specific lesions in DNA.Induction of error-prone repair
following replication block may be a major means by which bulky
adducts lead to mutation (Schaaper et al., 1982). The basic concept
for this mutational mechanism is that when the normal progress of
DNA replication is stalled at bulky adducts (Reardon et al., 1990), a set
of new proteins is induced which allows DNA synthesis to proceed
past the blocking lesion, resulting in increased survival and markedly
increased mutagenesis (Figure 2). The stringent fidelity requirements
of the normal replicating complexes may not allow the stable
incorporation of a nucleotide opposite the lesion.Under SOS
conditions, however, these stringent requirements become relaxed.
Blockage of DNA replication followed by SOS-induction in bacteria29
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Figure 2. Mutagenesis by chemical carcinogens via depurination.30
cells seems to take place in eukaryotic cells (Schaaper and Loeb,
1981).
Modification of bases in DNA also leads to enhanced rates of
depurination (Singer and Kusmierek, 1982), as exemplified by the
potent mutagen AFB1 (Schaaper and Loeb, 1981). The primary N7-
guanyl AFB1 adduct is expected to weaken the N-glycoside bond of the
nucleotide such that elevated pH and temperature would result in
depurination, generating AP sites (Muench et al.,1983).Their
depurination, either spontaneously or enzymatically by specific N-
glycosylases removing damaged or unusual bases from the DNA, could
provide a much better substrate for error-prone bypass than does the
original blocking lesion (Schaaper et al., 1982).
AP sites are noninstructive, that is, devoid of information for
Watson-Crick base pairing.In the absence of template information,
the mutational specificity of AP sites may be depend on the properties
of polymerase and its affinity for particular deoxyribonucleoside
triphosphate (Strauss et al.,1982; Schaaper et al.,1983). Their
enhanced mutagenicity is largely dependent on induction of the error-
prone SOS response (Sambamurti et al.,1988).Site-specifically
modified oligonucleotides resembling the product of bulky carcinogen
adduct and a guanine breakdown product have been used for in vitro
polymerization experiments, or in an E. coli system involving a
damage-induced SOS response (O'Connor and Stohrer, 1985). Results
showed that there is an overwhelming and unexpected specificity for
the insertion of adenine nucleotides at such sites.This specificity
correlated well with those which have AP sites as intermediates
because there is a strong preference for insertion of dAMP at AP sites,31
leading to distinctive G to T or A to T transversions (Kunkel, 1984;
Sagher and Strauss, 1983).Sequence-level in vitro studies were
carried out for the specificity of mutagenesis by activated aflatoxin
(Foster et al.,1983; Sambamurti et al.,1988).Using in vitro
modification of the lac gene followed by transfection into appropriate
E. coli cells, resulting forward mutations in the lac gene segment were
identified by DNA sequencing.The results showed that the major
base-substitutions induced by AFB1 was a G to T transversion. G to A
transitions were reported as well.
Other carcinogens causing bulky DNA adducts, benzo[alpyrene-diol-
epoxide(BaPDE) and N-acetoxy-2-acetylaminofluorene (AAAF), also
specifically induce G to T transversions (Foster et al., 1983; Eisenstadt
et al., 1982).Their similar mutagenic specificities may simply derive
from their common ability to create AP sites in DNA and form the
preferential insertion of adenine opposite such lesions, although the
sites that are best induced are not the same (Drinkwater et al., 1980).
Activation in the c-K-ras gene, not in H-ras and N-ras, has been
detected inliver tumors of rats chronically exposed to AFB1
(McMahon et al., 1986) and identified as both G to A and G to T base
changes in codon 12 (McMahon et al., 1987).Sinha et al. (1988)
reported that activated ras oncogenes were detected in all AFB1-
induced rat liver tumors, and N-ras activation (3 out of 4 tumors) is
most frequent as well as K-ras activation being found.Recently,
McMahon et al. (1990b) presented an "unexpected" report that N-ras
mutation is involved in all AFB1-induced rat liver tumors (5 of 5) as
well as in all normal rat liver (3 of 3).32
N- methyl -N'- nitro- N- nitros oguanid ene (MNNG)
MNNG is a direct-acting methylating agent that specifically (>90%)
induces G to A transitions due to the methylation of the 06 position of
guanine and the predicted mispairing property of 06-methylguanine
(06-MeG) adducts (Kohalmi and Kunz, 1988; Burns et al.,1987).
Consistent with methylating agents whose principal mutagenic
product is 06-methylguanine lesion, N-methyl-N-nitrosourea (MNU)
(Zarbl et al., 1985) and N-nitroso-N-methyl-N-d-acetoxybenzylamine
(NMAB) (Horsfall and Glickman, 1988) cause the G to A transition
mutation preferentially.
N-nitroso compounds such as MNNG and MNU have a common
alkylating intermediate, the methyl diazonium ion, following metabolic
activation (Horsfall et al., 1990).They react primarily with oxygen
(Singer and Kusmierek, 1982) and may have the same site specificity
in mammalian cells as in E. cols (Burns et al., 1987).
The molecular electrostatic potential of the 06 position of guanine
can be influenced by the adjacent base pairs and the accessibility of a
particular 06 position to a reactive methylating species would be
expected to be influenced by the local DNA helix geometry.In
addition, the 5' nucleotide may influence the degree to which a
thymine residue is incorporated opposite an 06-MeG, or the extent to
which the 3' to 5' editing function of the polyrnerase is able to remove
the mismatched base.The relative reactivity of the 06 position of
guanine is increased substantially when a purine occupies the 5'
flanking position (Richardson et al., 1987). The 5' flanking sequence
appears to influence the mutability of SNI-type direct-acting alkylating
agents (Dolan et al., 1988). G to A transitions were found to be six33
times more likely to occur at G:C base pairs at which the guanine
residues were flanked (5') by a purine, particularly guanine, than at
those preceded by a pyrimidine (Burns et al.,1987).MNU, for
example, exclusively activates the H-ras proto-oncogene of rat by a G
to A transition at the second guanine residue in codon 12 (GGC to
GAC) (Zarbl et al.,1985), even though the same event at the first
guanine in codon 12 also produces an activated phenotype (Seeburg et
al., 1984).
Adaptation of E. coli involves the induction of the ada gene which
codes for 06-MeG-methyltransferase, which repairs alkylating agent-
induced DNA lesions (Richardson et al.,1987).Evidence for an
adaptive response in mammals which paralleled the E. coli response
was identified in mammals liver tissues and was more ambiguous
(Yarosh, 1985).
Most mutations induced by MNNG are the result of the altered
templating property of the 06-MeG lesion.This major premutagenic
lesion, is able to mispair with thymine yielding a G to A transition at
the subsequent round of replication (Richardson et al., 1987; Burns et
al.,1987; Basu and Essigmann, 1988), but this mispairing is
competitive with the normal incorporation of dCMP (Abbott and
Saffhill, 1979).
An activatedc-H-ras gene was identified in 10T1/2 cells
transformed by exposure of a parental, wild-type population to MNNG
(Smith and Grisham, 1987).The specificity of MNNG and MNU for
activation of ras proto-oncogenes only by mutation of codon 12 may be
explained by the fact that the major mutation induced in codon 61 by
methylating agents results in a termination codon which would be34
biologically inactive (Vousden et al., 1986). MNU seems to be directly
responsible for the activation of H -ras 1 because of its highly labile
nature under physiological conditions (Zarbl et al., 1985).
The case of A:T to G:C transitions might be explained by the
incorporation of 06-methyldeoxyguanosine (MeG) triphosphate from
the alkylated nucleotide pools, opposite thymidine residues in the
template strand (Singer and Kusmierek, 1982).
7. 12- d imethylbenzI al anthracene (DMBA)
While most carcinogen metabolites react preferentially with
guanine residues, the in vivo metabolite of DMBA generated in mouse
skin reacts almost exclusively with adenine residues (Cheng et al.,
1988). From the cultured mouse embryo cells exposed to 7,12-DMBA,
substantial amounts of adenosine adducts were formed (Dipple et al.,
1983).Over 90% of mouse skin tumors initiated with DMBA have a
specific A to T transversion at the second nucleotide of codon 61 of H-
ras gene (Quintanilla et al., 1986; Balmain and Pragnell, 1983). The
frequency of this mutation was dependent on the initiating agent used,
but not on the promoter, suggesting that the mutation occurs at the
time of initiation. The same type of mutation, A to T transversion at
the second nucleotide of codon 61 of H-ras, was reported in human
melanoma tissue (Sekiya et al., 1984) as well as in mice skin tumors
induced by nitroso-compound (Anderson et al., 1989).
Polymerase chain reaction (PCR).
PCR is an in vitro DNA amplification procedure and circumvents to
a great extent the need for subcloning and traditional biological
plasmid amplification. A schematic diagram for the PCR principle is
illustrated in Figure 3.The method is,like the natural DNA35
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Figure 3. Schematic diagram for the PCR principle.36
replication process, based on the repetition of a set of three steps:
denaturation of templates, annealing of primers and primer extension
(Oste, 1988).The primers flanking the region to be amplified are
hybridized to different strands of a DNA template in a relative
orientation such that their extension products overlap (Mullis et al.,
1986).The amplified target sequence (or short transcript) becomes
overwhelmingly dominant by its exponential accumulation. However,
the amount of long transcript will increase only arithmetically because
the quantity of original template remains constant. Thermostable DNA
polymerase from the bacterium Thermus aquaticus (Taq) retains its
activity after heat denaturation of the DNA, which simplifies the PCR
reaction.In addition its higher optimum temperature (7075 0C)
significantly increases the specificity, yield, and length of targets to be
amplified.Recently, PCR has been widely used, particularly in the
analysis of ras gene activation in cancer.
Total precision of amplification parameters remained elusive. As a
result, the concentration of each component, the temperature and
time for given cycle segments are all subject to minute variations
(Erlich, 1989).PCR primers are typically 20-25 bases in length
having an average GC content (around 50%) and random base
distribution avoiding substantial secondary structure.They have
different sequences and are not complementary to each other,
particularly at the 3' ends.Primer dimer concatenation is an
amplification artifact often observed, especially when many cycles of
amplification are performed on a sample containing very few initial
copies of template.Sequences not complementary to the template
can be added to the 5' end of the primers. These noncomplementary37
5' extension sequences become incorporated into the double stranded
PCR product and provide a means of introducing restriction sites
(Scharf et al., 1986) or regulatory elements (e.g., promoters) (Stoflet
et al., 1988) at the ends of the amplified target sequence without
decrease of the amplification efficiency.In the later cycles of
amplification these primers anneal primarily to the amplified products
rather than to the original genomic sequences, and are therefore fully
complementary.Degenerative oligonucleotides primers, a mixture of
oligonucleotides equal in size but containing various sequences,
allowed significant amplification relative to unique oligonucleotides for
PCR (Mack and Sninsky, 1988) in the case where the exact target
sequence is unknown. For highly degenerate primers, it is preferable
that the most unambiguous sequence be situated at the 3'-end of the
primer (Eh len and Dubeau. 1989).
The concentration of MgC12 can have a profound effect on the
specificity and yield of an amplification by Taq DNA polymerase and
should be adjusted in parallel with high concentrations of sample DNA
and dNTP's usually containing EDTA chelator. Generally, excess Mg+2
will result in the accumulation of non-specific amplification products
and insufficient Mg+2 will reduce the yield.
Boiling and quenching on ice of the high molecular weight target
DNA prior to PCR greatly enhances the amplification process, because
full denaturation of the chromosomal DNA in the first few critical
rounds of amplification determines the quantity of the final product.
Insufficient heating during the denaturation step is one of the most
common causes of failure in a manual PCR reaction.In addition, it38
would inactivate proteases in DNA samples, if any, and prevent
degradation of the Taq polymerase.
Because the primers are present in large excess over the DNA
template, the formation of the primer-template complex will be
favored over the reassociation of the two DNA strands when the
temperature is lowered.Higher annealing temperatures generally
result in much more specific product with higher yield, because
poorly matched primer-template hybrids dissociate and there are
fewer nonspecific extension products to compete for the polymerase.
The exponential accumulation of PCR amplification products is not
an unlimited process.Eventually, a level of amplification is reached
where more primer-template substrate has accumulated than the
amount of enzyme present is capable of completely extending in the
allotted time (Saiki et al., 1988). PCR can amplify DNA segments by
million fold, and potentially as high as billion fold. The fact that the
PCR technique allows the specific amplification of discrete fragments
of DNA makes it much easier to detect nucleic acid fragments (Oste,
1988), reducing the nucleic acid complexity by nearly the same factor.
Therefore, specific hybridization with much shorter oligonucleotide
probes than is typically feasible and decreased stringencies of
hybridization are possible (Mack and Sninsky, 1988).
PCR is also directly coupled with existing DNA sequencing methods
because the amplified fragment typically becomes the most prominent
species in the sample.This eliminates the need for cloning and
purifying the DNA sample to be sequenced (Engelke et al., 1988; Wong
et al., 1987). By using unequal molar amounts of the two amplification
primers, it is possible in a single step to amplify a single-copy gene39
and produce an excess of single-stranded DNA of a chosen strand for
direct sequencing or for use as a hybridization probe (Gyllensten and
Erlich, 1988).
The misincorporation rate of PCR DNA synthesis is extremely low
(1for each 9,000 nucleotides polymerized) (Tindall and Kunkel,
1988). Sequence analysis of directly cloned PCR products allowed the
quantitative evaluation of its specificity and fidelity (Scharf et al.,
1986).During PCR many types of DNA damage such as baseless sites,
inter-and intramolecular cross-links would slow down or completely
block the enzyme polymerization. Thus damaged DNA molecules in
the amplification reaction can be expected either not to be replicated
at all or to be at a replicative disadvantage, so that intact molecules
will amplify preferentially (Paabo and Wilson, 1988).
The extremely high sensitivity of the PCR technique easily results
in amplification of trace amounts of contaminants."Carryover" of
contaminating DNA is a most serious problem in PCR, and usually
occurs by aerosolization of amplified samples when tightly capped
tubes are once opened.Pipetting devices which do not physically
separate tips from the material being pipetted is another source of
"carryover" problem because even a single copy of DNA carrying known
"control" sequences can be inadvertently amplified a million fold.It is
strongly recommended to set up PCR reaction mixes in areas separate
from PCR product handling and not to open the capped tubes being
amplified until PCR is complete (Lo et al., 1988; Kwok and Higuchi,
1989). Each room should be completely equipped with its own set of
appropriate pipetting and storage devices. Dedicated pipettes, vessels
and solutions for DNA preparation, reaction mixing and sample40
analysis will minimize across contamination.Nothing should be
exchanged between rooms.It was recommend to use positive
displacement pipetting devices which have disposable tips and
plungers when pipetting the DNA. Contamination with target DNA is
much less likely since target DNA, as opposed to amplified DNA, is
generally of high molecular weight.As a strategy for detection of
contamination, it was suggested that a negative control consisting of
all PCR reagents minus the DNA template should be included in every
amplification (Schochetman et al., 1988).
Detection methods for point mutations.
Gene transfer assays and Southern blot hybridization have been
major experimental approaches to detect and characterize the genetic
variation in human oncogenes (Varmus, 1984).Mutated ras genes
were first identified by their ability to transform the established mouse
cell line NIH3T3 after DNA transfection (Goldfarb et al., 1982, Santos
etal.,1982, Shih and Weinberg,1982).Mainly due to the
laboriousness of the assay, however, the transfection assay was not
suitable for the analysis of large number of tumors. Biological assay of
gene transfection has relative low sensitivity of detection particularly
for large size genomic DNA such as the K-ras gene (Bos et al., 1987a)
and DNA transfected into mammalian cells was reported to be mutated
at high frequency (Ca los et al., 1983).NIH3T3 transfection assay
cannot discriminate whether a mutation is present in one or in both
alleles because of its inability to detect the normal alleles (Bos et al.,
1984).
Recently, physical methods that detect base substitutions (or point
mutation) causing genetic diseases or oncogene activation have41
become important tools in several studies as well as ras gene mutation
in cancer research.Five of the methods most frequently used to
detect point mutations are briefly described as followings.
Restriction endonuclease digestion.
An end-labeled oligonucleotide probe with the wild-type sequence
is hybridized to an in vitro amplified target genomic sequence.A
mismatch within the restriction site prevents cleavage of the duplex,
revealed by the appearance of different size of labeled fragments
(Embury et al., 1987, Saiki et al., 1985).Using a similar method,
mutations ofthe human c-H-ras oncogene at codon 12 were
distinguished from the normal cellular counterpart by the loss of a
restriction endonuclease site thus creating a diagnostic restriction
fragment length polymorphism (RFLP). A mutation eliminating CCGG
or GAGG sequences that is specifically recognized by the restriction
endonuclease Hpa II/Msp Ior Mnl I,respectively, destroys the
cleavage siteat codon 11 (GCC), codon 12 (GGC)in human H-ras
(Feinberg et al., 1983, Muschel et al., 1983; Kraus et al., 1984) and
codon 12 (GGA), codon 13 (GGC) in normal rat (Zarbl et al., 1985). Or
as a non-radioactive assay, the amplified fragment by PCR was then
directly digested to detect RFLP (Deng, 1988).In the case of the
human K-ras proto-oncogene, however, the normal sequence of codon
12 was not part of any sequence specifically recognized.Instead, two
specific mutations create new restriction sites (Santos et al., 1984). A
similar case was also reported in codon 61 of H-ras during mouse skin
chemical-induced carcinogenesis (Quintanilla et al., 1986).
Due to the easy handling of this technique, it has been often used
for mutational screening assay. However, these specific sequences for42
certain restriction endonuclease sites are limited to a few cases. Many
point-mutations do not lead to an altered restriction site.Therefore,
only a limited set of mutations, if any, can be detected (Valenzuela and
Groffen,1986).
Denaturing gradient gel electrophoresis.
DNA molecules that differ by single-base substitutions can be
separated from one another by electrophoresis through an ascending
gradient of denaturants in a polyacrylamide gel.The method can
determine if DNA duplex contains any mismatch.Where DNA
molecules migrate into a gradient of ascending concentration of
denaturant, they undergo an abrupt decrease in mobility at a
characteristic depth, resulting in specific positions and patterns on
the gel running. Even a single-base substitution can cause two DNA
molecules to melt at significantly different temperatures (Fischer and
Lerman,1983,Myers et al.,1987).The gradient of denaturants used
in the system, urea and formamide, appears to be fully equivalent to a
temperature gradient. The structural difference caused by a mismatch
in heteroduplex substantially lowers the melting temperature or
equivalently lowers the denaturant concentration at which melting
takes place.
Mismatch cleavage.
RNAse A or Si nuclease cleaves single stranded RNA or DNA,
respectively.Total cellular RNA or genomic DNA is hybridized to end-
labeled normal antisense RNA molecules.Mismatches within RNA-
RNA or RNA-DNA heteroduplex caused by mutations in cellular RNA or
in genomic DNA, respectively, leaves the single strand generating the
labeled short fragment of RNA by RNAse A (Forrester et al.,1987,43
Winter et al., 1985).Similarly labeled normal DNA molecules can be
hybridized to genomic DNA and any mismatch at a mutation site is
cleaved by S1 nuclease (Myers et al.,1985).Heteroduplex DNAs
containing mismatched base pairs were also cleaved chemically
following the treatment with a single strand specific modifying
chemical agent (e.g., hydroxylamine for cytosine-specific modification)
(Cotton et al., 1988; Montandon et al., 1989). These approachesare
useful in the localization and diagnosis of mutations and in the
estimation of expression level or mutation ratio between normal and
mutant alleles in the same cell. However, mismatch cleavage assays do
not provide the actual sequence at the mutation site andsome
mismatches in certain sequence are not detected (Engelke et al.,
1988).
Direct sequencing of PCR products.
As a direct way to detect any base changes, sequencing of specific
regions of genomic DNA became possible after the invention of PCR
(Engelke et al., 1988).Addition of a internal third primer for the
sequencing reaction (Wrischnik et al., 1987) and the use of unequal
molar amounts of PCR primers to generate a predominant single
strand (Gyllensten and Erlich, 1988) greatly improved the resolution
of direct sequencing results and facilitated the automation for large-
scale sequencing projects (Innis et al., 1988).Recently, ras oncogene
alleles were characterized from carcinogen-induced animal tumors
used direct sequencing of PCR product without purifying and cloning
(McMahon et al., 1987). Furthermore, concurrent signals inone base
were used as an estimation of mutation ratio.However, some direct
sequencing resulted in sequencing gels with high background bands44
that obscured the reading of the sequence (Wrischnik et al., 1987).
Therefore, usually the results are confirmed by oligonucleotide
hybridization analysis (Wong et al., 1987; Neri et al., 1988).
Mutation-specific oligonucleotide hybridization.
Usually the binding of the oligonucleotide probe dependson its
length and GC content (Wood et al., 1985).Tetramethylammonium
chloride (TMAC, Me4NC1) binds preferentially to A:T base pairs
(Shapiro et al., 1969) and raises the melting temperature (Chang et
al., 1974). At 3 M Me4NC1, this displacement is sufficient to shift the
melting temperature of A:T base pairs to that of G:C base pairs
(Melchior and von Hippel, 1973), reducing the problem toa simple
dependence on length of the hybrid (Wood et al., 1985). For different
oligonucleotides, therefore, empirical determination of a suitable
hybridization and wash temperature is unnecessary (Conner et al.,
1983, Verlaan-de Vries et al., 1986).Additionally, for the melting of
long DNA, this shift results in remarkable sharpening of the melting
profile, i.e., natural DNAs that melt over a range of 5 to 10 0C in the
presence of sodium ion,melt within 1 0C in Me4NC1 (Chang et al.,
1974).This is caused by the fact that unequal relative base pair
stability with different G:C contents are responsible for most of the
breadth of the melting transition (Melchior and von Hippel, 1973).
Since even a single-base-pair internal mismatch within a 17-mer
probe decreases the Td of the hybrid 5 to 10 0C (Wallace et al., 1981,
Wallace et al., 1979, Wood et al., 1985), correct mutantscan be found
relatively easily.After hybridization with a "mutant" probe of known
sequence, the filters are washed with 6X sodium-chloride and sodium-
citrate (SSC) buffer to remove the unbound labeled probe, then rinsed45
with Me4NC1 at room temperature to substantially remove SSC because
Na+ will compete for Me4N+ binding (Orosz and Wetmur, 1977).
Originally, the procedure for mutation analysis was developed based
on selective hybridization of mutation-specific oligodeoxynucleotide
probes to genomic DNA without Ln vitro amplification (Bos et al., 1984,
Conner et al., 1983).Unambiguous conclusions were difficult when
screening highly complex genomic DNA of low abundance because
detection level is limited (Bos et al.,1984, Wood et al.,1985;
Valenzuela and Groffen, 1986) and the intensity of labeling at the
hybridized gene fragment for each probe was significantly proportional
to gene dosage (Conner et al., 1983). The procedure has been greatly
improved both in sensitivity and speed by an in vitro amplification step
(Verlaan-de Vries et al., 1986; Kozma et al., 1987).Allele-specific
oligonucleotide hybridization procedures can then be used to detect
the presence of single base changes in short segments of DNA if the
exact nature of the mutation is known in advance (Vousden et al.,
1986). The procedure can also be applied advantageously wheneveran
exact match to an oligonucleotide probe is desired, a pool of
oligonucleotide probes are used (Wood et al., 1985), or PCR produces
spurious bands on gel separation.The use of non-radioactive
oligonucleotide probes provides an easier way to screen the mutations
(Bugawan et al., 1988).
This procedure, widely used for identifying the mutation in
conjunction with PCR, provides qualitative data on the type of
mutations in positive cases as well as conclusive identification of the
negative ones (Verlaan-de Vries et al.,1986; Kozma et al.,1987),46
which are not readily achievable with biologicalassays involving
NIH3T3 cell-transformation (Bos et al., 1987a).
Fish models.
Fish models are useful not only as environmental in situ monitors of
aquatic pollution but as alternative vertebrate non-mammal species for
comparative carcinogenesis studies (Powers, 1989).The rainbow
trout (Oncorhynchus mykiss) has been most extensively used for
toxicologic and carcinogenic research since the early 1960's.Even
though trout have a long generation time (23 years) and have no
homologue for several mammalian organs (e.g., lung, mammary glands
and urinary bladder), they have unique characteristics highly desirable
for most biomedical research and specific research problems (see
Bailey et al., 1984, Table 4).In comparison with mammalian systems,
however, little is known about the molecular basis of carcinogenesis,
particularly any involvement of oncogenes in trout neoplasia. Recently,
there have been several fish studies at the molecular level.The ras
gene was cloned from goldfish liver DNA (Nemoto et al., 1986) and the
c-myc gene was isolated from rainbow trout (van Beneden et al.,
1986), which showed a remarkable similarity to their mammalian
counterparts. Without the identification of the ras gene sequence, ras
gene mutations were reported in Atlantic tomcod (Wirgin et al., 1989)
and winter flounder (McMahon et al.,1990a).Because of the
ubiquitous occurrence, and the evolutionary high conservation of ras
proto-oncogene in eukaryotes, ras gene activations have often been
detected in chemical carcinogenesis animal studies.Therefore the
isolation and the mutational analysis of a trout ras gene could prove to
be significant in this chemical carcinogenesis model.The primary47
Table 4. Features of rainbow trout system.
1) Up to 6,000 offspring are available.
2) One hundred or more individuals can be housed in thesame
rearing unit.
3) The very low rearing cost is conducive to random sampling
and statistical comparisons.
4) Diet requirements are known and can be carefully controlled
from the time of hatching.
5) Growth and metabolism can be altered by changing water
temperature.
6) Several routes of exposures to chemicals are available.
7) Trout can endure long periods of starvation without illness or
mortality.
8) Trout remain sexually immature for approximately 18 months
and do not reproduce until 2 or more years of age. This
permits experiments to be run without the influence of
sexual hormones.
9) Trout is very sensitive to the carcinogenicity of AFB1.
10) The spontaneous rate of tumor incidence is very low.48
focus of our study was to identify the partial ras gene in normal trout
liver DNA using in vitro gene amplification and then to investigate
several carcinogen-initiated tumors in rainbow trout for evidence of
ras gene point mutations. We used the oligonucleotide hybridization
technique with position-specific degenerative and allele-specific 20-
mer probes to screen whole PCR mixtures of each sample and
confirmed findings using dideoxynucleotide sequencing of cloned PCR
products.49
MATERIALS AND METHODS
Tissue samples and DNA extraction.
Rainbow trout reared at the Toxicology and Nutrition Hatchery of
Oregon State University were treated with 80 ppm AFB1 (Calbiochem)
in the diet for two weeks. Nine months after AFB1 exposure, test fish
were sacrificed and tissue samples were immediately frozen in liquid
nitrogen.Fish treated with 50 ppm MNNG for 30 min and one that
was treated with 5 ppm DMBA for 24 hours by bath exposure were
sacrificed18 months later.Chemical carcinogen waste was
deactivated and disposed according to Armour et al. (1986). DNA was
extracted from homogenized samples of normal tissues and primary
liver tumors by lysis in buffer containing 10 mM EDTA, 100 mM Tris-
HCI (pH 7.5), 50 mM NaCl, 2% NaDodSO4, and proteinase K (100
14/m1) overnight at 37 'DC with mild shaking. DNA was then purified
by phenol/chloroform(Boehringer Mannheim Biochemicals)
extraction and 95% EtOH (Aldrich) precipitation.Resuspended
samples in TE buffer (10 mM Tris-HC1, pH 7.4, 1 mM EDTA) were
treated with RNAse (1001.1.g/ml,Sigma).Phenol/chloroform
extraction and EtOH precipitation were repeated.
cDNA synthesis and random primer labeling.
Total RNA was extracted from normal trout liver tissue using
commercial RNAzo1 (Cinna/Biotecx) and passed through an oligo(dT)-
cellulose column (5Prime-3Prime) to isolate the mRNA. cDNA was
then synthesized using a commercial cDNA synthesis kit from
Bethesda Research Laboratories. The first strand of cDNA synthesized50
was used as the template DNA for PCR Random primers labeling of
DNA probes was performed using [alpha-32P1 dATP (NEN; 3000
Ci/mmol) and a commercial random labeling kit (Bethesda Research
Laboratories).
Oligonucleotide synthesis.
All the oligonucleotides used in this study were synthesized at the
Gene Research Center of Oregon State University using an Applied
Biosystems 380A DNA synthesizer.
PCR.
To amplify the fragment sequences of previously identified trout H-
and K-ras gene, we used the panel of oligonucleotide primers shown
in Figure 4 and Table 5.Sequences spanning 90 base pairs (bp) and
111 by includes codons 12 and 13 of the ras genes of trout genomic
DNA or cDNA. For the sequence analysis around codon 61, a 126 by
sequence between primer 38 and c79D was amplified.Using trout
liver cDNA as a PCR template, a 237 by PCR product covering exon 1
and part of exon 2 in trout ras gene was amplified between RO1 and
c79D primers.For each PCR reaction, 1 pg of DNA and 30 pmol of
each of the two primers were added to a 50 pl reaction mixture
containing 10 nmol of each dNTP (Pharmacia) and 1 unit of Taq DNA
polymerase (Beckman) in PCR reaction buffer (10 mM Tris-HC1, pH
8.3, 50 mM KC1, 1.5 mM MgC12).Forty-five cycles of denaturation at
94 0C for 30 sec, annealing at 45 0C for 30 sec, and extension at 70 'DC
for 30 sec were done on an automated heat-block (Ericomp).In the
first 2 cycles, however, the denaturation step was done for 1.5 min
per cycle and the DNA sample was boiled for 5 min prior to adding
Taq polymerase for the complete denaturation of genomic DNA and for(A)
exon 1 intron
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01D 1-01- c37
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Figure 4. PCR amplification of a portion of a ras gene.Primers are
indicated by arrows and probes are by squares; The expected
size of PCR products from genomic DNA (A) and cDNA (B) are
represented with base pairs (bp); and "R" indicates a rat
sequence, "c" indicates a complementary sequence, and "D"
indicates a degenerate sequence.52
Table 5.PCR primers sequence.Degenerate sequences are
presented as small capital letters.
RO1: ATG ACT GAG TAT AAA CTT GT
Rc30 :TTC AGA ATC ACT TTG TGG AT
OlD : ATG ACTG GAA TAT AAG CTTG GTG G
c37 : CTC GAT GGT GGG GTC ATA TTC
38 :GAC TCG TAC AGG AAG CAG GTG G
c7 9D :GAAG GAAA GCC CTC TcCC AGTCT GcC
Table 6.Position- & allele-specific probes for oligonucleotide
hybridization.
D : A,C,T
1213
H normal: G GGG GCA GGA GGT GTG GGC A
H12 D1 :- D -
H12 D2 :- -D
H13 D1 :- D-- -
H13 D2 :- -D-
H12 Ti
H12 Al
H12 T2
H12 A2
H13 T2
H13 A2
. -T-
Mm.
_T
K normal: G GGT GCT GGA GGT GTT GGG A
K12 D1 :- D-
K12 D2 :- -D
K13 D1 :- D-
K13 D2 :- -D
61
H normal: GCA GGT CAG GAG GAG TAC AG53
the inactivation of DNAse, if any. PCR products were then mixed with
0.1 volume of loading dye, and separated through 4% acrylamide slab
gel electrophoresis. The gel was stained with ethidium bromide (1
µg /ml) and photographed with UV transillumination.
Oligonucleotide hybridization.
Three to five gl aliquots of the PCR mixtures were transferred to
Zeta-Probe nylon filter (Bio-Rad) with a slot-blot manifold (Bethesda
Research Laboratories) or by Southern blotting with 0.4 M NaOH
(Reed and Mann, 1985).Replicate blots were simultaneously
hybridized to a panel of 20-mer synthetic oligonucleotide probes
shown in Table 6.Oligonucleotide probes (30 pmoles) were end-
labeled with 30 pmoles of [gamma -32P] ATP (NEN; 3000 Ci/mmol) by
means of T4 polynucleotide kinase (Pharmacia or Promega) and
purified through a Quick-Spin G-25 Sephadex column (Boehringer
Mannheim Biochemicals). Washing of filters was performed in a 3 M
TMAC (Aldrich) solution (50 mM Tris-HC1, pH 7.6, 2 mM EDTA, 0.1%
NaDodSO4) at 61 'DC with constant shaking (Verlaan-de Vries et al.,
1986; Wood et al., 1985) slightly modified from MutaLyzerTM2 manual
(ClonTech).Following the final washing with 6X SSC, the blot was
exposed to X-ray film (Kodak, X-Omat/AR) for 40 min or overnight at
room temperature.
Cloning and plasmid preparation.
After the digestion of pUC10 vector with Sma I restriction enzyme,
the linearized pUC10 with blunt ends was combined with PCR
products concentrated using Centricon-30 filtration units (Amicon) at
a molecular ratio of 1:100 and ligated using 1 unit of T4 DNA ligase
(Bethesda Research Laboratories) in 4 0C for overnight (Ferretti and54
Sgaramella, 1981). One pl of the 5 times-diluted ligation mixture was
used to transfect 25 )11 of DH 5 alpha competent cells (Bethesda
Research Laboratories).
Selected white colonies on LB agar plate containing 100 mg/ ml of
ampicillin, 10 p.1 of 10% X-gal (5-bromo-4-chloro-3-indolyl-beta-D-
galactoside : Bethesda Research Laboratories), and 10 p1 of 100 mM
IPTG (isopropylthio-beta-galactoside : Bethesda Research Laboratories)
were screened by the oligonucleotide hybridization method. Plasmid
DNAs from probe-positive clones were prepared according to the
procedures described in Davis et al. (1986).
Sequencing.
Sequencing reactions were done according to a modification of
Taq-Track sequencing system (Promega). One pg of plasmid DNA was
denatured in 0.4 M NaOH and neutralized with potassium acetate.
After the precipitation with EtOH, 2 pmol of M13/pUC primer was
added in the resuspended sample in Taq buffer. A 25 IA mixture was
prepared containing 2 IA of extension mix, 2 p.1 of [alpha -32 P] dATP
(NEN; 3,000 Ci/pmol), 5 units of Taq DNA polymerase.After
incubation at 37 0C for 5 min, 6 p.1 of reaction mixture was added to 1
pi of each deoxy-/dideoxy-nucleoside triphosphate in the separate
tubes. After incubation at 70 'DC for 5 min, the sequencing reactions
were stopped by the addition of 3 p.1 of 80% formamide dye mixture.
Four pi of the heat-denatured reaction mixtures were loaded onto a 8
M urea/5% acrylamide gel.Following the electrophoresis in 50 0C,
the gel was dried and exposed to X-ray film (Kodak, X-Omat/RP) at
room temperature.55
RESULTS
I. Identification of a ras gene in trout liver.
New set up for PCR.
Following the occurrence of a PCR "carryover" problem in the
laboratory, the PCR experiment was resumed in a room which was
physically separated from that in which the PCR products were
handled.All preparations for PCR and all DNA extractions from the
tissue samples were completed in a room which had not been used for
DNA manipulation. Stock solutions were entirely replaced. PCR buffer
was prepared without the general use of gelatin and was maintained as
frozen aliquots.New DNA samples were prepared and a new set of
primers was synthesized. When the DNA samples were taken, positive
displacement pipettips(Gilson Medical Electronics,France:
reordered from Rainin Instrument Co. Inc.) were used to prevent
carryover from sample to sample.For each PCR run, a negative
control without a DNA template was performed along with samples to
detect any trace amounts of carryover.
Since PCR is an elusive reaction, the "standard" PCR condition is
summarized in Table 7. To obtain maximum yield and improved
quality, this condition was slightly modified in accordance with
specific cases. New primers, RO1 and Rc30, based on the rat K-ras
sequence (Table 5), were synthesized and used for 90 by PCR
amplification for the first exon of trout genomic DNA (McMahon et al.,
1990a). The G:C base pair contents of the RO1 and Rc30 primer were
low (respectively, 30 and 35%), and the annealing temperature of PCR56
Table 7."Standard" PCR condition for 50 1.11 reaction.
Tris-HC1 (pH 8.3) 10 mM
KC1 50 mM
MgC12 1.5 mM
Each Primer 0.6 [tM
Each dNTP 0.2 mM
Taq. enzyme 4 U
Template DNA 0.5 pig
Mineral oil 35 gl
Template DNA at 100 0C for 5 min, then on ice.
Step-Cycle program (45 cycles)
45 0C 30 sec
70 0C30 sec * 4.5 min (last cycle)
94 0C30 sec 1.5 min (first 2 cycles)57
at 45 0C produced a major 90 by band on acrylamide gel
electrophoresis.To obtain the information on the entire mRNA
sequence, a PCR using RO1 and (dT)24 primers with cDNA template
was performed, but failed to yield a discrete band. Reamplification of
the above reaction with a third primer (Ohara et al., 1989) produced
no clearer result.
To optimize the PCR, different amounts of template DNA and dNTP
were tested (Figure 5). An increase in PCR products was observed as
the template amounts were increased.Fractionation of the DNA
template by physical shearing through the syringe or by vigorous
vortexing was helpful for complete DNA denaturation.At dNTP
concentrations less than 0.2 mM, no PCR products were detected on
the gel. A newly prepared dNTP mixture which failed to produce any
PCR product was found to have an absorbance peak at 270 nm. An
equal ratio of each dNTP was mixed again and tested for the PCR,
which yielded expected PCR products and had an absorbance peak at
260 nm. Although it was not known what happened in the former
dNTP mixture, scanning of the dNTP mixture to assure an absorbance
peak at 260 nm was essential to assure good PCR reactions (Figure 6).
Higher annealing temperature (i.e., from 37 0C to 45 0C) improved the
reaction yield to some extent (data not shown).
Oligonucleotide hybridization.
To establish the oligonucleotide hybridization technique in the
laboratory, a preliminary experiment with a human K-ras sequence
was performed until the trout ras sequence could be identified.As
indicated by Verlaan-de Vries et al. (1986), 111 by of the first exon
was amplified by PCR from normal human and rat genomic DNA with a58
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GGT (Gly) sequence at codon 12 of theras gene.For the mutated
sequence controls, the plasmids containing the human mutated K-ras
for GTT (Val) and the viral K-ras for AGT (Ser),were used as the PCR
templates. From the viral K-rte template,a 216 by PCR product was
prepared, using 0 1D and c72D (5'-CAT GTA CTG GTCCCLI CAT QIGC-
3') primers.Based on the human K -ras,sequence, oligonucleotide
probes (Gly : 5'-GGA GCT GGT GGC GTA GGC AA-3' andVal : 5'-GGA
GCT GTT GGC GTA GGC AA-3')were purchased (ClonTech), each with
a single base difference at the second position of codon 12 of theras
gene.The amounts of PCR productswere estimated by ethidium
bromide staining of the gel (Figure 7). The resultsindicated that each
oligonucleotide probe was specifically bound toits unique sequence,
but not to alleles differing by one nucleotide. A ser-specificprobe (5'-
GGA GCT AGT GGC GTA GGC AA-3') also showed specificbinding (data
not shown).
Washing of the blots was seeminglya critical step in sequence
differentiation, and strict temperature controls andconstant shaking
were important factors.However, oligonucleotide probe bindingwas
often not absolutely specific andsome cross-binding among the
negative controls was found to producea background signal. Scanning
with the densitometer was useful for quantificationestimation and is
subsequently described in Figure 14. Thepresence of large amounts
of the normal allele sequence in PCR mixturesseems to have
enhanced the extent of background binding of mutated oligonucleotide
probes (for example, see Figure 8, lane 3).
90 by trout sequence.
Since the rat sequence was used for the primer synthesis,as216 by
111by
61
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Figure 7.Specificity of oligonucleotide hybridization. PCR products of
normal human genomic DNA (lane 1), normal rat genomic DNA
(lane 2), human mutated K-ras plasmid (lane 3), and viral K-ras
plasmid (lane 4) were hybridized with 20-mer probes specific
for the codon 12 point mutation (Gly : GGT and Val : G'IT) of the
human K-ras sequence.111 bp_
90 bp
1.1
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rr
1.1
6-4
12345 6
Gly probe
Val probe
PCR products of
1. Normal Human Genomic DNA (111by :Gly)
2. Human Mutated K-ras plasmid(111by :Val)
3.Primer Only Control
4. Normal Rat Genomic DNA (90 by :Gly)
5. Normal Trout Liver Genomic DNA (90 by:?)
6. Trout Liver Tumor Genomic DNA(90 by:?)
62
Figure 8.Oligonucleotide hybridization of trout PCR products. PCR
products of normal human genomic DNA (lane1), human
mutated K-ras plasmid (lane 2), negative control of primer-only
PCR product (lane 3), normal rat genomic DNA (lane 4), normal
trout liver DNA (lane 5), and trout liver tumor DNA (lane 6) were
hybridized with 20-mer probes specific for the codon 12 point
mutation (Gly : GGT, Val : GTT) of the human K-ras sequence.63
described by Wogan (McMahon et al., 1990a), this investigation ought
to determine how the "trout DNA" PCR product compared to the rat
sequence.Using normal rat liver DNA as a positive control, normal
trout liver DNA and trout liver tumor DNA were used for the PCR
template. Separation by acrylamide gel electrophoresis indicated that
the trout as well as mammalian PCR had one major band with a clear
background, and that the negative control generated no products
(Figure 8, lane 3).PCR products from normal human genomic DNA
and mutated human K-ras plasmid were then used as controls for
oligonucleotide hybridization.Oligonucleotide hybridization with
probes derived from normal (GGT) and mutated (GTT) human K-ras
showed that the expected PCR products were obtained using the
mammalian DNA template and that the trout sequence differed from
mammalian sequences in at least one base in the region of the probe,
such that no hybridization occurred.
Direct sequencing of PCR products was performed for the trout ras
sequence, but did not yield readable sequence. To sequence the PCR
product indirectly, it was ligated with a blunt end pUC10 plasmid for
transformation.Clones selected with random labeled PCR product
probe were then sequenced. The sequencing result for the 90 by PCR
product from normal trout liver genomic DNA is shown in Figure 9,
compared with the rat K-ras and the goldfish ras gene. Since it was
identified using rat K-ras primers, this sequence is hereafter referred
to as the trout K-ras.However, its entire sequence or functional
homology to mammalian ras genes is still unknown.
Several ras sequences from different species were compared
around codons 12 and 13 (Table 8), suggesting that each species has a64
R01-Rc30: ATG ACT GAG TAT AAA CTT GTT GTG GTG GGT
Rat K-ras: --G --A --T --A
Goldfish : --A --A --G --G --C --A --G
(Rol)_*** *** *** *** ****** **
R01-Rc30: GCT GGA GGT GTT GGG AAG AGT GCC TTA ACT
Rat K-ras: --T --C --A --C --G --G
Goldfish : --C --G --C --T C-C --C
R01-Rc30: ATC CAG CTC ATT CAG AAT CAC TTT GTG GAT
Rat K-ras:
Goldfish :
** ****** *** *** *** ***
(Rc30)
Figure 9. Trout sequence of the 90 by PCR product with primers RO1
and Rc30.Star marks represent the positions of the primer
sequence.
Table 8. Sequence comparison around codons 12 and 13 of ras genes.
1213
Trout K-ras :G GGT GCT GGA GGT GTT GGG A
Human K-ras :T --A --T --C --A --C
Rat K-ras :T --A --T --C --A --C -
Mouse K-ras :T --A --T --C --A --C
Trout H-ras : --G --A --G --C
Human H-ras : --C --C --C --G --C
Rat H-ras : --C --C --G --A
Human N-ras :T --A --A --T
Mouse N-ras :T --A --A --T
Goldfish ras : A --G --C --G --C
Chicken ras - --A --C65
distinct ras sequence which can be differentiated by oligonucleotide
hybridization when at least two of the base pairs are different. The
oligonucleotide probes, reflected in Figures 5 and 6, are one base
shifted toward the 3'-end.This information can be used for the
identification of a specific ras gene, as well as the point mutations of
trout tumor DNA. An additional trout ras sequence, referred to as
trout H-ras (Mangold et al., in preparation), wasidentified with
consensus degenerative primers (01D). TroutH-ras differs from trout
K-ras at more than two bases in the oligonucleotide probe region.
For confirmation of the 90 by sequence, newly prepared DNAfrom
a tumor and two normal liver tissues wereused. These PCR products
showed the same sequence as previously described in Figure 7.To
investigate the expression of this sequence in mRNA, cDNA wasused
as a PCR template, producing the 90 byproducts shown in Figure 10,
lane 2.Determining the same sequence from cDNA confirmed the
presence in genomic DNA as well as the expressionin mRNA. With a
genomic DNA template, a 111 by PCR product was prepared usingthe
two pairs of RO1c37 and OlDc37primers (Figure10,
respectively, lanes 3 and 4). The whole mixture of PCR products was
then blotted onto a nylon membrane in 0.4 M NaOH and probedwith
oligonucleotides specific for trout H-ras and trout K-ras sequences,
indicating the base difference. The results indicate that ROI and 01D
5' primers were able to produce different sequences of PCRproducts
from the same trout genomic DNA. A 237 by PCR product wasalso
made with the cDNA template and a pair of ROI and c79D primers.
This PCR product was then ligated into pUC10 by a blunt-endligation
reaction and used for transformation. Though cloning occurred at a141
105bp.
78 bp."
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Figure 10.Oligonucleotide hybridization of trout PCR products using
different primers and templates.PCR products (left panel) of
genomic DNA with R01-Rc30 (lane1), cDNA with R01-Rc30
(lane 2), genomic DNA with R01-c37 (lane 3), and genomic DNA
with 01D-c37 (lane 4) were hybridized with trout K-ras (upper
right panel) and H-ras (lower right panel) specific 20-mer
oligonucleotide probes.67
low degree of efficiency, the clones containing the PCR product insert
were selected by PCR product probe labeled by the random priming
method.Selected clones with the 237 by PCR product insertedwere
sequenced, proving inclusion of a 90 by sequence (Figure 11).
The nucleotide sequence was then compared, and the homologous
percentages among several ras genes in their counterparts of actually
amplified sequences (197 bp), excluding the primer sequences at both
ends, are shown in Table 9. Most were homologous to 80% or greater;
Trout K- and H-ras genes showed more than 90% homology, and were
more closely related to the goldfish ras gene than to either the
mammalian ras or the chicken ras genes. The predicted amino acid
sequence of trout K-ras, compared to the other ras sequences, showed
only one residue difference at codon 69 where asparagine replaced
asparate.In the case of chicken ras (Westaway et al., 1986) and
goldfish ras (Nemoto et al.,1986), the predicted amino acids
sequence did not show any difference from the mammalian ras gene.
Table 9.Nucleotide sequence homology of trout ras PCR products to
other vertebrate ras gene sequences within identified region.
Homology Percentage
Trout K-rasTrout H-rasGoldfish ras
Human K- ras 83 82 82
Rat K-ras 84 83 82
Human H-ras 83 86 89
Human N-ras 81 82 78
Chicken ras 82 82 81
Goldfish ras 88 89
Trout H-ras 91R01-c79D
Rat K-ras
Human H-ras
: ATG
(R01) -***
R01-c79D
Rat K-ras
Human H-ras
R01-c79D
Rat K-ras
Human H-ras
:GCT
--C
ACT GAG TAT AAA
--G --A --G
*** *** *** ***
GGA GGT
--T --C
--C
: ATC CAG CTC
--A --A
--G
R01-c79D : GAA
Rat K-ras :
Human H-ras
R01-c79D : AGG
Rat K-ras
Human H-ras :C--
R01-c79D :TGT
Rat K-ras :---
Human H-ras :--C
R01-c79D
Rat K-ras
Human H-ras
:CAA
--G
GTT
- -A
- -G
GGG
--C
--C
ATC CAG
- -T
TAT GAC CCC ACC
--T --T --G
AAG CAG GTG GTG
--A --A --A --A
C
CTG CTG GAC ATC
--C --T --T
T__
GAG GAG TAC AGC
T
R01-c79D TAC ATG AGG ACA GGG
Rat K-ras
Human H-ras : C-C --C ---
** *** ***
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10
CTT GTT GTG GTG GGT
--G --A --T --A
--G --G --C
*** **
20
AAG AGT GCC TTA ACT
G --G
--G C-G --C
30
AAT CAC TTT GTG GAT
- -C --T --C
40
ATC GAG GAC TCG TAC
- -A --T --C
50
ATT GAC GGA GAG ACG
--T --A --C
CTG GAC
--C
60
ACA GCA GGT
--T --C --C --C
70
GCC ATG AGG AAC CAG
G
-AG GGC TTT CTT
*** *** *** ***_
( c79D )
Figure 11.Trout sequence of the 237 by PCR product with primers
RO1 and c79D.69
II. Mutational analysis of trout ras genes.
PCR scheme.
DNA samples from trout tumors initiated by several chemical
carcinogens, including AFB 1, MNNG and DMBA, were subjected to the
PCR to amplify the fragment of the trout H-ras gene, as illustrated in
Figure 4 and Table 5.In previous studies, the two ras genes, trout H-
ras and K-ras, from the genomic DNA and cDNA of normal liver tissues
were identified (Mangold et al., in preparation).Based on the partial
trout ras sequence information, the presence of ras gene mutations in
codons 12 and 13 was analyzed by the combination of the PCR and the
oligonucleotide hybridization assay.For in vitro amplification of the
target sequence in exon 1, a set of oligonucleotides (01Dc37 or ROl
c37) was used as primer pairs, and trout tumor genomic DNA was
used as template DNA. To amplify the exon 1 sequence of the trout H-
ras gene from genomic DNA, the first intron sequence was once used
for the synthesis of the 3'-primer oligonucleotide.However, the PCR
yield using the OlD and the intron-sequenced 3'-primer was low with
many diffuse bands, such that c37 primer was used.
Five sets of 20-mer oligonucleotides with four degenerative
position-specific and a normal sequence were synthesized for the
probes around codons 12 and 13.Allele-specific oligonucleotide
probes were then synthesized for the identification of specific point
mutations in accordance with the resultsof position-specific
oligonucleotide hybridization.Systematic analysis of the trout ras
genes mutations made it easy to screen the incidences and the
specificities in a large number of tumor samples (Figure 12).To70
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Figure 12.Schematic diagram for systematic mutational analysis.
Extracted DNA from chemically-induced trout tumors were used
as PCR templates.Whole mixtures of amplified PCR fragment
were analyzed for evidence of point mutations using position-
and allele-specific oligonucleotide hybridization. PCR products
ligated into plasmid were cloned and selected by oligonucleotide
hybridization. Mutant positive clones were then sequenced.71
measure the ratio between normaland mutated allele, the PCR
products were cloned and the colonies were hybridized withboth
normal and mutated specific oligonucleotide probes. Toconfirm the
result obtained by oligonucleotide hybridization assayof the whole
mixture of PCR products, selected colonies with a mutatedprobe were
then sequenced.
Controls for oligonucleotide hybridization.
Because the oligonucleotide hybridization technique poses
difficulties for the availability of positive mutated sequence controls,
the controls for each probe were enzymatically polymerizedby using
the probe as a 5'-primer (Rochlitz et al., 1988) andthe amplified 111
by PCR product as a template DNA. This reaction yielded amajor
single band (85 by PCR product), into which each probe wasphysically
incorporated, with a clean PCR product background. Fivereamplified
PCR products, including four position-specific mutated sequencesand
a normal sequence, wereseparated on a 4% acrylamide slab gel
electrophoresis and stained with ethidium bromide (Figure13).Five
replicate blots, each containing five control PCR products, werethen
simultaneously hybridized with each of the probes.There was no
substantial cross-reaction among each of the PCRproducts.
Reamplified 85 by PCR products were then used formutated
sequence controls in the first andthe second positions of codons
12/13 to screen the point mutations in the primarytumor PCR
samples.As an alternative control sequence, allele-specificprobes
were used as primers forreamplification of the 111 by PCR products,
yielding the 85 by PCR products.
Normal and mutated sequence controls (90 bp) werealso12345
4,
es
Blots probed with
A : H normal
B: H12 D1
C : H12 D2
D : H13 D1
E :H1 3 D2
72
Figure13.Positive controls for position-specific ras probes.
Reamplification, using oligonucleotide probe around codon
12/13 as a 5'-end primer, produced 85 by PCR products, which
were stained with ethidium bromide on 4% acrylamide gel.
These PCR products incorporated by H normal, H12 D1, H12
D2, H13 D1, and H13 D2 probes, respectively, are numbered as
1 through 5.The upper panel shows five replicate acrylamide
gel of the five PCR products. The lower panel shows the specific
probing of the five gel blots.73
enzymatically polymerized from PCR product inserted plasmids with
RO1 and Rc30 primers. These PCR product controls were mixed and
hybridized with oligonucleotide probes to investigate the linear
relationship between signal strength and the control amounts (Figure
14).A dot blot autoradiogram was scanned and the heights were
measured.Subtracting the background signals caused by the cross
reactions, the heights of the signal peak were plotted against the each
of control amounts.The slope in the graph presents the specific
activity of the oligonucleotide probe, and the binding of two probes (H
normal and H12 T2) was dependent upon the control amounts. This
experiment demonstrated a possibility that the amount of each allele
in each sample can be calculated quantitatively.
AFB1-induced trout liver tumors.
Southern blot.
Similar to the procedure for the control blots, five replicate
Southern blots of whole PCR product mixtures from 14 primary trout
tumors initiated by AFB1 were simultaneously hybridized with five
different mutated codon 12/13 probes for trout H-ras mutational
analysis.Only one band responded with a clear background (Figure
15).It was of interest to note that the normal ras gene sequence was
dominant in the tumor DNA PCR products. However, it could not be
determined whether the normal allele was excessively amplified in the
tumor tissue, or if only a small portion of the cell population within
the primary tumor carried a mutated ras allele.
Of the 14 trout liver tumors induced by a single AFB1 exposure, 10
samples (72%) showed evidence for a mutated allele in codons 12 or
13 of the trout H-ras gene. Specifically, probe H13 D2 was positive for123456
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Figure 14.Densitogram of control PCR products mixtures.PCR
product controls (H normal and H12 T2) were mixed at certain
ratios, and hybridized with H normal, H12 D2, H12 T2, and H12
A2.Densitometry of dot blot autoradiogram, after the
subtraction of background signal, showed that the bindings of
oligonucleotides are nearly proportional to the amounts of PCR
products.44
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Figure 15.Position-specific probing of tumor DNA PCR products. PCR
products (111 bp) of trout liver DNA induced by AFB1 were
separated on 4% acrylamide gel.Five replicates of each
Southern blot were hybridized with each position-specific probe.
Samples were numbered arbitrarily from left (1) to right (14).76
tumor DNAs 4 and 7, with all other DNAs showing some binding which
was interpreted as background.Probe H13 D1 was negative for all
DNAs, whereas probe H12 D2 indicated strong binding to DNAs 1, 2,
6, 9, 10, 11, and 13, and possibly 5. H12 D1 bound strongly to DNA
14 and possibly to 3 and 5.This initial binding study thus provided
evidence for 7 of 10 mutations (70%) in the second position of codon
12, which is an often mutated site for ras-protein activation and tumor
induction. No mutations were indicated in the first position of codon
13 for any of the tumors. Of these mutations, two were indicated in
the second position of codon 13 and one mutation in the first position
of codon 12.
Dot blot.
To repeat the previous oligonucleotide hybridization result, a dot
blot assay with newly prepared PCR products was performed with
results similar to that for the Southern blot assay. This time, allele-
specific probes were included for the identification of specific
mutations. However, only the A and T mutations for the allele-specific
oligonucleotides were tested since it was known from prior report
(McMahon et al., 1987) that the possible mutations caused by AFB1 are
either A or T.Allele-specific hybridization for 14 primary tumor PCR
products supported the results of the previous experiment with
position-specific hybridization (Figure 16).It was of interest that all of
the mutations in the second position of codons 12 and 13 indicated a
G to T transversion mutation.However, a mutation in the first
position of codon 12 indicated a G to A transition mutation, which is
in agreement with previous reports on the rat liver model (McMahon
et al., 1987; Sinha et al., 1988; McMahon et al., 1990b). To improvew wiPso
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Figure 16.Position- and allele-specific dot blot analysis.Newly
prepared PCR products of trout liver DNA induced by AFB1 were
applied to five duplicate dot blots, which were then hybridized
with position- and allele-specific oligonucleotide probes.
Numbering for 14 samples follows the pattern established in
Figure 15.Positive controls for H12 D1 (Cl) and H13 D2 (C2)
were applied.78
representation, a densitogram was employed for the hybridized blot
shown in Figure 16 (Figure 17). From the densitogram,a variation of
H-ras normal probe binding was obviously observedamong the tumor
DNA PCR products. On the other hand, comparison of theH12 A2
probe binding with the H12 T2 probe binding indicatedthat the
signals in H12 A2 could be consideredas a background, which was not
clear in the autoradiogram picture (Figure 16).In this respect, H12
D2 binding at PCR products of tumor DNA 3was considered as a
background. Because of the background problem in the H12 A2 probe
shown in Figure 16, a dot blot assay with new PCR products from the
same samples was repeated, including assay of the allele-specific
control PCR products (Figure18).This result confirmed the
previously obtained results, and allele-specific controls for H12 T2 and
H12 A2 failed to bind with normal probe, but bound with H12 D2
probes.
Additional 16 samples of AFB1-induced liver tumorswere analyzed
for trout H-ras mutations, using the same methodology detailedin
Figure 16 (Figure19).Of 16 tumor samples tested, 10 (63%)
appeared to carry mutant alleles, and 8 samples indicateda mutation
in the second position of codon 12, showing a G to T transition
mutation. Two by each of the H12 D1 and H13 D2 probes showed
mutations, but the H13 D1 and allele-specific mutationswere not
analyzed. Normal liver genomic DNA was also analyzed to determine
the spontaneous mutations of the trout ras genes (Figure 20).In the
normal counterpart tissue from the same individual containing the
chemically induced tumors, no trout H-ras gene mutations around
codons 12 and 13 were found.2
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Figure 17. Densitogram of dot blot analysis. For improved resolution,
the autoradiogram from figure 16 was scanned with the
densitometer.80
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Figure 18.Dot blot analysis in the second position of codon 12. To
repeat the results shown in Figures 15 and 16, PCR products
were prepared and hybridized with the probes specific to the
second position of codon 12.Controls were allele-specific H12
T2 (T) and H12 A2 (A).H12 12
1 23 45678910 11 1213 14 15 16
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Figure 19. Dot blot analysis of 16 samples of AFB1-induced liver tumors. The procedure was identical to
that established in Figure 16.
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Figure 20.Mutational analysis of normal trout liver tissues.PCR
products of eight normal liver tissues were separated on
acrylamide gel (upper right panel), and after Southern transfer,
probed with trout normal H-ras probe (upper left panel). The
lower four dot blots were probed with the trout H-ras position-
specific probes as indicated, showing no mutation in this region.83
PCR clones screening and dideoxy sequencing.
To determine the ratio between normal and mutated allele in
tumor tissues, the PCR clone screening method was applied.The
whole mixture of PCR products from tumor DNA 6 was directly cloned
into pL1C19 vector by blunt-end ligation.Individual clones were then
screened by position-specific probes, as well as a H normal probe, to
select the base-changed PCR inserted clones and to determine the
ratio between normal and mutated allele (Figure 21).In tumor DNA 6,
only 1 of 20 H-ras positive colonies indicated a mutated sequence.
These clones were used for dideoxy sequencing in order to confirm
the results by allele-specific oligonucleotide hybridization of whole
PCR mixture samples (Figure 22).
The same strategy was applied to DNAs 2, 7, and 14. The evidence
for H-ras mutation in 14 trout liver tumors induced by AFB1 is
summarized in Table 10. The PCR clone screening assay was used to
confirm the presence and distribution of mutated alleles.This may
have contributed substantially to the accuracy of the quantitative
estimations of allelic frequency in the primary tumor DNA.Of the
recombinant clones containing PCR products, most revealed a normal
sequence, as was also reported for AFB1-induced rat liver tumor DNA
by McMahon (1990b). PCR products containing a point mutation were
only a small proportion of the total reaction population, which
suggests that the majority of the cells within the tumor still contained
normal ras sequence alleles or that non-neoplastic cells were mixed in
the tumor tissue.Direct sequencing of the PCR products may not
revealthepointmutationsindicatedby sequence-specific
oligonucleotide hybridization in situations where a minor portion ofH12- normal H12D2 Probe
.41101116
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Figure 21.Position-specific probing of cloned PCR product from
single tumor DNA.Individual clones were hybridized with
normal and H12 D2 probes.AAG Lys :16-1
GGC Gly :15-1
GTG Val :14E
GGT Gly: 13
GGA Gly : 12 1
GCA Ala :ii-E
GGG Gly :10E
GTG Val :9 E
GTG Val :8 E
Normal
GA TC
OM»
Mutant
G ATC
1&
41111.
410 4.51w GTA Val :12
Figure 22. DNA sequence analysis of cloned PCR products. The positive clone with a H12 D2 probe
(Figure 21) was sequenced (codon 12 GTA) with a normal sequence clone (codon 12 GGA),
confirming the results for an allele-specific probe (H12 T2) hybridization (Figure 16).Table 10. Summary of oligonucleotide probing and sequencing analysis. Trout H -ras, gene mutations
in AFB1-induced liver tumors were analyzed, based on position- and allele-specific oligonucleotide
hybridization, PCR product colonies screening, and sequencing.
TumorTotal PCR DNATotal PCR DNA Mutant : NormalMutant Colonies
DNA(Position-specific(Allele-specific Colonies (Sequencing)
probes) probes) (Position-specific
probes)
14 Codon 12 : ?GA AGA 1:8
1 Codon 12 : G?A GTA
2 G?A GTA 1:8
6 G?A GTA 1:19
9 G?A GTA
10 G?A GTA
11 G?A GTA
13 G?A GTA
4Codon 13 : G?T GTT
7 G?T GTT 4 :18
3Normal : GGA GGT
5 GGA GGT
8 GGA GGT
12 GGA GGT
Codon 12 : AGA
Codon 12 : GTA
Codon 12 : GTA
Codon 13 : GTT87
the ras gene alleles are mutated.
Trout K-ras mutation.
The same methodology adopted for the trout H-ras mutation
analysis was applied for the analysis of the trout K-ras mutations inthe
same 14 AFB1-induced troutliver tumors. PCR fragments (90 bp)
with a pair of RO1 and Rc30 primers were analyzedby five sets of
position-specific oligonucleotide probes, including normal K-rasprobe
(Figure 23).In a Southern blot for the trout K-ras normal probe, three
85 by negative controls, K12 D1 (N1), K12 D2(N2), and K13 D2 (N3)
and one 85 by positive control (P) were included.All tumor DNA PCR
products bound strongly with the K-ras normal probe suggestingthat
the PCR of liver tumor DNAs amplified the troutK-ras sequence
differing from trout H-ras.For the mutated sequence probes, one
negative (N) and one positive (P) control PCRproducts were used in
dot blot assays. Since binding of 4 position-specificprobes showed no
variations among tumor DNA PCR products,this binding was
interpreted as background. Although these tumor samplesshowed a
high frequency of trout H-ras mutations, no mutations wereobserved
in the trout K-ras gene.This result was not surprising since each
tissue had the specific type of ras gene mutation aspreviously
reflected in studies of human and animal carcinogenesis(Tables 2 and
3).
MNNG- and DMBA-induced trout tumors.
Mutational analysis of 15 trout liver tumors induced by MNNG was
performed with the trout H-ras sequence, indicatingthat 13 of the
samples (87%) were mutated. The specific point mutation was aG to
A transition mutation in the first (3 of 13) andthe second (10 of 13)tagatiffiStittiati4,
N1 N2 N3 P
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Figure 23.Dot blot analysis of trout K-ras mutation.Mutations in
codons 12 and 13 of trout K-ras were analyzed with the samples
identical to those in Figures 15 and 16. The upper panel shows
an autoradiogram of the 14 tumor DNA PCR products after gel
resolution, Southern transfer, and probing with K normal probe.
The lower four dot blots were probed with the trout K-ras
position-specific probes as indicated.89
positions of codon 12 (Figure 24).However, 12 trout kidney tumors
induced by MNNG failed to reveal mutations of the trout H-ras (Figure
25).It was of interest to note that a high incidence of the trout H-ras
mutations in liver tumors by MNNG was not detected in kidney
tumors.
Mutation analysis at codon 61 was not completed owing to the loss
of most DMBA tumors, but PCR amplification spanning 126 by
between the 38 and c79D primers was successful with other minor
bands. The PCR products of four DMBA-induced liver tumors and two
normal livertissues were hybridized with a normalallele
oligonucleotide probe of codon 61 (Table 6), showing positive signal at
126 by on autoradiogram (Figure 26).1 234567891011 12 13 1415
1 234567891011 12 13 1415 C
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Figure 24.Dot blot analysis of MNNG-induced liver tumor DNA.
Mutations in codons 12 and 13 of trout H-ma were analyzed with
15 trout liver tumors induced by MNNG.H normal
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Figure 25. Dot blot analysis of MNNG-induced kidney tumor DNA.
Mutations in codons 12 and 13 of trout H-ras were analyzed with
PCR products of 12 trout kidney tumors induced by MNNG
(upper right panel). The upper left panel shows Southern blot
hybridization with trout H-ras normal probe. In the dot blot
assay (lower panel), four mutated PCR productcontrols, H12 D1
(C1), H12 D2 (C2), H13 D1 (C3), and H13 D2 (C4), were used.126 by
92
H normal Probe atCodon 61
Figure 26.Oligonucleotide probing of trout H-ras sequence around
codon 61.Following the amplification of exon 2 of trout H-ras
from DMBA-induced trout liver tumors and normal livers, 126
by of PCR products were separated on acrylamide gel (left
panel).Southern blot of PCR products were probed with a
normal sequence oligonucleotide probe around codon 61 (right
panel).93
DISCUSSION
Trout model for carcinogenesis studies.
Since the activated ras oncogene was first identified in human
tumor cells in 1982 (Table 1), the mutation analysis of oncogenes has
received great attention. The principal research questions have been
directed at the causes of oncogene activation and the sequential
moleculareventsassociatedwiththedifferentstagesof
carcinogenesis.Because the etiology of tumor initiation and
development can be carefully controlled in animal model systems,
mice and rats have been widely used for the studies of chemical
carcinogenesis.Knowledge of the reproducible induction of specific
types of mutations by particular chemical carcinogens has been
accumulating, wherein the ras gene family has proved to be a highly
prevalent target sequence in animal models as well as in human
tumorigenesis (Tables 2 and 3).The trout model system possesses
certain unique features(Table5),including essentially zero
background tumor incidence and persistent carcinogen-DNA adduct
due to poor DNA repair activity (Walton et al., 1984).Furthermore,
with the lower research cost, a sufficient number of animals can be
used to provide a firm statistical basis for the comparison of data.
Moreover, this approach reduces the need to use rats or other
mammalian species, supporting the important basic research
processes from the studies of non-mammalian species.At the
molecular level, studies of trout, separated from mammals by 400
million years of evolutionary divergence, can be used to provide an94
essential basis for comparative research with rodent models.
Unfortunately, the molecular genetics of carcinogenesis has been
little studied in fish systems.Recently, several fish model studies at
the molecular level have been reported. A ras gene was cloned and
sequenced from goldfish (Nemoto et al., 1986). The sequence of the
myc gene has been identified from the rainbow trout (Van Beneden et
al., 1986). Mutations of K-ras genes in winter flounder (McMahon et
al., 1990a) and Atlantic tomcod liver tumors (Wirgin et al., 1989) have
been reported, but without firm knowledge of the ras sequences
involved.Prior to the analysis of ras gene mutation in rainbow trout
tumors, substantiated information on the ras gene sequence was
required. In this study, a ras gene in trout liver was identified using in
vitro PCR amplification. Based upon this information on the trout ras
gene, mutations in experimentally induced trout tumors were analyzed
with a combination of the PCR and oligonucleotide hybridization
methods.
PCR carryover.
The ability to amplify discrete DNA fragments by factors of millions
to billions by PCR provides a great advantage for the detection and
manipulation of nucleic acid in trace amounts.However, extreme
precautions must be taken with the PCR preparation and environment
(Lo et al., 1988; Kwok and Higuchi, 1989).From this aspect, there
have been a number of interesting reports using the PCR. In spite of
their large evolutionary divergence, McMahon et al. (1990a) reported
an identical ras, gene sequence for winterflounder and the rat.In
addition, it was reported that N-ras mutations were detected in all
normal rat livers as well as in AFB1-induced rat liver tumors95
(McMahon et al., 1990b). A clear possibility is that these puzzling
findings reflect PCR plasmid carryover problems.
Identification of trout K-ras.
To confirm the sequencing result for the 90 by PCR product using
RO1 and Rc30 primer pairs, the experiment was repeated using newly
prepared trout genomic DNA from normal livers as well as liver
tumors. The primers were also changed to produce large sizes of PCR
products, 111 by and 237 bp, using RO1 and c37 from genomic DNA
template or RO1 and c79 from cDNA template, respectively.These
PCR products included the identical sequence to the 90 by PCR
product, suggesting that this sequence was a real trout sequence
expressed in mRNA. For complete sequence information on the trout
K-ras gene, it will be useful to screen for clones within a trout liver
cDNA library.
For further investigation of the identity of the ras gene, the
Southern blot of trout genomic DNA could be probed with trout PCR
product probes.Preliminary experimentation using the PCR product
of human K-ras plasmid demonstrated a signal in the Southern
hybridization of trout genomic DNA. Although a tomcod tumor DNA
transfectant also was detectable using a mammalian K-ras probe, this
assay may not be quite specific for the identification of the trout ras
sequence, particularly in the N-terminal conserved sequences:thus,
no definitive conclusions were drawn from this experiment.Another
method of obtaining the transforming sequence from trout tumors is
the NIH3T3 transformation assay with trout tumor genomic DNA.
However, the application of the PCR with transformed NIH3T3 DNA
template and R01/Rc30 primers produced mouse-specific PCR96
products which failedto hybridize with trout K-rasspecific
oligonucleotide probes.
Oligonucleotide hybridization.
For the detection or screening of point mutations in human tumors
or animal systems, it is important to select an appropriatemethod
from among several available techniques. PCR is a favorite method for
target sequence amplification.As shown in Tables 2 and 3,it is
obvious that oligonucleotide hybridization method has contributed
much to the screening of point mutations.In addition, the relative
amounts of normal and mutated alleles could be determined by
scanning the signals of the normal and mutated probes.The
oligonucleotide sequence of an identified trout H-ras gene was
compared with the reported sequences from several vertebrate
animals (Table 8).Since all species differ by more than one base, each
specific sequence can be determined by theoligonucleotide
hybridization technique.
Positive controls for the hybridization of each oligonucleotide probe
were prepared by the reamplification of diluted 111by PCR products
as a template, rather than using genomic DNA(Rochlitz et al., 1988).
The physical incorporation of each oligonucleotide probe into 85 by
PCR products provided a better yield and good quality products
(Figure 13).Because of their smaller size and the lack of the 5'-
primersequence,thesecontrol PCR productseliminated
experimental errors of false identification or the amplification of
carryover DNA.This approach provides the advantages that large
numbers of samples can be screened quickly and sensitively.
Moreover, it allows the detection of all possible single-base mutations97
at every possible position and an allele-carrying two or more base
substitutions as long as the mutation-specific oligonucleotide probes
are synthesized (McMahon et al.,1990b). This technique could also
be applied to sequence-specific quantification in combination with
densitography since each oligonucleotide probe binds proportionally
to the target sequence (Table 14).
Mutation analysis of trout tumors.
DNA from 10 of 14 (72%) trout liver tumors initiated by AFB1 were
mutated in codons 12 and 13 of the trout ras genes based on a
combination of PCR and oligonucleotide hybridization methods. The
major point mutation of the ras gene, for 7 of 10 point mutations, was
a G to T transversion at the second positionof codon 12.This
confirmed that codon 12 is one of the critical positions for ras gene
activation and the guanine base at the 5'-flanking position influences
the carcinogenic activity of the second base of codon 12 (5'-GGA-3').
Two of the point mutations also had a G to T transversion mutation at
the second position of codon 13.However, one tumor showed
evidence of a G to A transition point mutation at the first position of
codon 12, and there were no mutations in the first position of codon
13.An additional 16 trout liver tumors initiated by AFB1 were
analyzed and demonstrated a similar pattern. A total of 10 samples
(63%) showed evidence of mutations, 8 of which were major G to T
mutations in the second position of codon 12. One each from the H12
D1 and H13 D2 probes also indicated a mutation. By comparison, the
same experiment with normal liver tissuesshowed no trout H-ras
mutations (Figure 20).Similar mutation results were reported in
aflatoxin B 1-initiated rat tumors (McMahon et al., 1987; Sinha et al.,98
1988; McMahon et al., 1990b).This AFB1 mutational spectrum in
both trout and rat liver tissue has important implications for patients
with high chronic AFB1 exposure.Further analysis of the subtype
populations of ras gene mutation within individual human liver tumors
and mutation frequencies at various stages of tumor development
following AFB1 initiation are suggested.
From the results of oligonucleotide hybridization (Figures 15 and
16), it was obvious that PCR products containing point mutations were
only a small proportion of the total reaction population. Thisindicated
that the majority of the cells in the tumor mass had a normal ras gene
sequence.Of the recombinant clones containing PCR products
previously identified by sequence specific hybridization as containing
point mutations, most revealed a normal sequence(Figure 21 and
Table 10).PCR-clones screening assay confirmed the presence and
distribution of mutated alleles with respect to the total number of
clones screened The ratio between normal and mutated allele in trout
liver tumor induced by AFB1 ranged up to about 20%,which is
comparable to the ratio for the rat (McMahon et al., 1990b).This
finding may offer a substantial contribution to the quantitative
estimation of the allelic frequency in the primary tumorDNA, but
further systematic examination is suggested.
This apparent low frequency of mutated sequences in tumor tissues
can be explained as follows; Activatingpoint mutations occur in only
one malignant cell type withinthe tumor (Watatani et al.,1989).
Clonal expansion of malignant cells containing activated ras genethen
give rise to the adenoma (You et al., 1989).Alternatively, connective
tissue or other non-neoplastic cells within tumors maysignificantly99
reduce the intensities of the mutation-specific signals (Grunewald et
al., 1989).For instance, K-ras gene mutations were not found in
hepatocellular carcinoma, but have been found in cholangiocarcinoma
(Tada et al., 1990). In this respect, the trout liver tumors without ras
gene mutations in this study may contain purehepatocellular
carcinoma. Methods are now available to test this hypothesis.
Double mutations of ras genes have been reported in different
alleles (Ned et al., 1988, Farr et al., 1988).Recently, triple ras gene
mutations within the same allele have been reported (McMahon et al.,
1990b).However, the results of this study failed to reveal the
existence of double mutations.
For tissue-specific mutations, it was found that trout liver tumors
induced by AFB1 revealed H-ras mutations, but there were no K-ras
mutations (Figures 15 and 23).Moreover, in the case of MNNG
carcinogenesis, trout liver tumors revealed a highfrequency of H-ras
mutation, but at the same time there were no H-ras mutations inthe
trout kidney tumors (Figures 24 and 25).These results provide
support for the concept that specific ras, genes areinvolved in certain
tissues, wherein tissue-specificfactors are involvedinthe
determination of carcinogen-specific mutation spectrum (Balmain and
Brown, 1988).This could offer an explanation of the ubiquitous
incidence of the ras gene mutations in eukaryotes, the importanceof
the ras gene products in cell physiology, and the conservationof ras
gene family throughout the courseof evolution.It is interesting that
the treatment of mouse (B6C3F1) and rat (Fischer 344)liver tumors
with an ethylating agent, diethylnitrosoamine (DEN), has shown ahigh
incidence of ras gene mutation (42%) in the mouse, but no mutations100
in the rat (Stowers et al., 1988). The repeated A to T transversion in
the second position of codon 61 of the H-ras gene has occurred in
mouse and rabbit skin tumors initiated by DMBA(Quintanilla et al.,
1986; Bizub et al., 1986; Leon et al., 1988) suggesting that certain
types of ras gene mutations are involved in tumor formation within
specific tissues.
The results of this investigation indicate that molecular events in
fish carcinogenesis resemble those of the higher vertebrates,
including man.This is the first substantiated study of ras gene
mutations in experimentally designed fish models. A high percentage
of consistently activating point mutations in the absence of
spontaneous mutations would indicate that fish could be an
inexpensive and acceptable alternative chemical carcinogenesismodel
system (Powers et al., 1989). Which factors determine the typeof ras
gene mutation is still open to be answered,but the reproducible
activation by chemical carcinogens suggests that DNAadduct
formation is a principal factor in causing mutations. Further analysis of
the expression of the mutated mRNA allele and its ratio tonormal
mRNA allele is suggested.The mutational spectrum of various
carcinogens in a variety of trout tissues, in comparison with thoseof
rodent animal systems, could increase our knowledge of the molecular
events involved in neoplastic transformations.101
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